Over a week ago |
Periodicals
|
Conagra (CAG) does not… Conagra (CAG) does not intend to hike prices in 2023, depending on the future path of inflation this year, Chief Financial Officer David Marberger said, according to Jennifer Williams-Alvarez, writing for the Wall Street Journal. Conagra, maker of Hunt's ketchup, Healthy Choice frozen meals and Slim Jim meat sticks, said even if inflation continues," and we take "any pricing, any adjustments would be moderate," according to the WSJ story. "Companies including burrito chain Chipotle Mexican Grill (CMG) and beauty products maker Ulta Beauty (ULTA). last year raised prices to combat higher costs, including for wages and raw materials." noted the WSJ. Reference Link ShowHide Related Items >><< - $491.55 /
-1.6802 (-0.34%) - 12/05/22
- Ulta Beauty CEO: Consumer is loving what we are offering
- 12/01/22
- Ulta Beauty reports SSS up 14.6% y/y
- 10/07/22
- Tanger Factory announces first Ulta Beauty store opening in Rehoboth Beach
- 09/07/22
- Jeld-Wen appoints Halligan to board of directors
- $1,512.34 /
+38.3 (+2.60%) - 01/09/23
- Chipotle announces 'Freepotle' rewards perk
- 01/03/23
- Chipotle introduces new lineup of Lifestyle Bowls
- 11/29/22
- Chipotle launches Mystery Boxes
- 11/28/22
- ASAP.com announces national food delivery agreement with Chipotle
- 01/10/23
- Conagra Brands exec Wise sells 50,000 common shares
- 01/09/23
- Conagra Brands CEO: Demand has been resilient and sales are strong
- 01/05/23
- Conagra Brands sees gross margin up around 300bps in 2H
- 01/05/23
- Conagra Brands cuts FY23 CapEx view to approximately $425M from $500M
- 01/06/23 RBC Capital
- Conagra Brands price target raised to $38 from $35 at RBC Capital
- 01/06/23 Stifel
- Conagra Brands price target raised to $44 from $35 at Stifel
- 12/29/22 Evercore ISI
- Conagra Brands price target raised to $42 from $40 at Evercore ISI
- 12/20/22 Morgan Stanley
- Conagra Brands upgraded to Overweight at Morgan Stanley on defensive positioning
- $1,512.34 /
+38.3 (+2.60%) - 01/05/23 Barclays
- Chipotle price target lowered to $1,450 from $1,510 at Barclays
- 10/27/22 Deutsche Bank
- Chipotle price target lowered to $1,699 from $1,708 at Deutsche Bank
- 10/26/22 Stephens
- Chipotle price target lowered to $1,760 from $1,900 at Stephens
- 10/26/22 KeyBanc
- Chipotle price target raised to $1,800 from $1,750 at KeyBanc
- $491.55 /
-1.6802 (-0.34%) - 01/06/23 Wells Fargo
- Ulta Beauty downgraded to Underweight from Equal Weight at Wells Fargo
- 01/06/23 Wells Fargo
- Ulta Beauty downgraded to Underweight from Equal Weight at Wells Fargo
- 01/05/23 Argus
- Ulta Beauty price target raised to $530 from $455 at Argus
- 12/12/22 Goldman Sachs
- Ulta Beauty downgraded to Neutral from Buy at Goldman Sachs
- $491.55 /
-1.6802 (-0.34%) - 12/01/22
- Ulta Beauty raises FY22 EPS view to $22.60-$22.90 from $20.70-$21.20
- 12/01/22
- Ulta Beauty raises FY22 revenue view to $9.95B-$10.0B from $9.65B-$9.75B
- 12/01/22
- Ulta Beauty reports Q3 EPS $5.34, consensus $4.15
- 12/01/22
- Notable companies reporting after market close
- $1,512.34 /
+38.3 (+2.60%) - 10/25/22
- Chipotle reports Q3 adjusted EPS $9.51, consensus $9.21
- 10/25/22
- Notable companies reporting after market close
- 07/26/22
- Chipotle reports Q2 adjusted EPS $9.30, consensus $9.04
- 07/26/22
- Notable companies reporting after market close
- 01/05/23
- Conagra Brands raises FY23 adjusted EPS view to $2.60-$2.70, consensus $2.47
- 01/05/23
- Conagra Brands reports Q2 adjusted EPS 81c, consensus 66c
- 01/04/23
- Notable companies reporting before tomorrow's open
- $1,512.34 /
+38.3 (+2.60%) - 01/11/23
- Subway looks into sale that could value company at over $10B, WSJ says
- 12/30/22
- Restaurant coalition sues to stop California fast-food wage law, WSJ says
- 12/01/22
- Twitter offers advertisers big incentives to boost spending, WSJ reports
- 11/10/22
- Chipotle removes paid ads from Twitter, Bloomberg reports
- 09/17/22
- IBM, CVS among cheap stocks not deserving to be in bargain bin, Barron's says
- $491.55 /
-1.6802 (-0.34%) - 01/06/23
- What You Missed On Wall Street On Friday
- 01/06/23
- What You Missed On Wall Street This Morning
- 12/12/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/02/22
- What You Missed On Wall Street On Friday
- $1,512.34 /
+38.3 (+2.60%) - 12/07/22
- #SocialStocks: EU rules against Meta, despite attempts to settle
- 11/28/22
- What You Missed On Wall Street This Morning
- 11/16/22
- #SocialStocks: Musk intends to pass Twitter reigns to someone else eventually
- 10/25/22
- Fly Intel: After-Hours Movers
- 01/05/23
- What You Missed On Wall Street On Thursday
- 01/05/23
- What You Missed On Wall Street This Morning
- 01/05/23
- Fly Intel: Pre-market Movers
- 12/20/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- $491.55 /
-1.6802 (-0.34%) - 12/01/22
- Ulta Beauty options imply 5.0% move in share price post-earnings
- 10/11/22
- Early notable gainers among liquid option names on October 11th
- 08/26/22
- Early notable gainers among liquid option names on August 26th
- 08/25/22
- Ulta Beauty options imply 5.6% move in share price post-earnings
- $1,512.34 /
+38.3 (+2.60%) - 10/25/22
- Chipotle options imply 6.3% move in share price post-earnings
- 07/27/22
- Early notable gainers among liquid option names on July 27th
- 07/26/22
- Chipotle options imply 6.1% move in share price post-earnings
- 07/25/22
- Largest borrow rate increases among liquid names
- 01/05/23
- Early notable gainers among liquid option names on January 5th
- 12/30/22
- Unusually active option classes on open December 30th
- 12/07/22
- ConAgra call volume above normal and directionally bullish
|
On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< - 01/06/23
- XPeng falls -15.8%
- 01/06/23
- XPeng falls -16.1%
- 01/06/23
- XPeng falls -11.3%
- 01/02/23
- Fly Intel: Top five weekend stock stories
- 01/06/23
- WWE rises 22.2%
- 01/06/23
- WWE trading resumes
- 01/06/23
- WWE says Vince McMahon returning to board, to undertake review of alternatives
- 01/06/23
- WWE to undertake review of strategic alternatives
- 12/05/22
- Ulta Beauty CEO: Consumer is loving what we are offering
- 12/01/22
- Ulta Beauty reports SSS up 14.6% y/y
- 10/07/22
- Tanger Factory announces first Ulta Beauty store opening in Rehoboth Beach
- 09/07/22
- Jeld-Wen appoints Halligan to board of directors
- $113.01 /
+2.635 (+2.39%) - 01/04/23
- Cathie Wood's ARK Investment bought 21K shares of Tesla today
- 01/03/23
- Cathie Wood's ARK Investment bought 176K shares of Tesla today
- 01/03/23
- Piedmont Lithium jumps 9% to $47.99 after amended pact with Tesla
- 01/03/23
- Piedmont Lithium amends agreement with Tesla
- 01/05/23
- Adeia enters long-term IP license renewal with Samsung Electronics
- 01/03/23
- InterDigital and Samsung to renew license agreement
- 12/22/22
- Stingray Group launches TV channels on Amazon Freevee, Samsung TV Plus
- 12/16/22
- Netlist announces claim construction order against Samsung
- 01/05/23
- Silvergate Capital falls -46.5%
- 01/05/23
- Silvergate Capital falls -43.6%
- 01/05/23
- Silvergate Capital falls -39.0%
- 01/05/23
- Silvergate not seeing clients closing accounts, but taking pause in crypto
RTX Raytheon Technologies - 01/05/23
- Raytheon Technologies awarded $208.7M U.S. Navy contract
- 12/22/22
- Raytheon Technologies awarded $317.42M Navy contract modification
- 12/21/22
- Raytheon Technologies awarded $412.6M Air Force contract
- 12/16/22
- Raytheon Technologies awarded $171.19M Navy contract modification
- $50.91 /
+1.2548 (+2.53%) - 01/06/23
- Pfizer: FDA accepts for priority review sBLA for 20vPnC
- 01/05/23
- 3D Systems appoints Bruce to Medical Advisory Board
- 12/29/22
- Pfizer discloses 5.38M share stake in Oric Pharmaceuticals
- 12/29/22
- Pfizer announces topline results from Phase 3 study of fidanacogene elaparvovec
- 01/06/23
- McDonald's to accelerate pace of restaurant openings, evaluate staffing levels
- 12/29/22
- Beyond Meat rises after McDonald's UK&I announces 'Double McPlant'
- 12/15/22
- McDonald's & U.S. logistics partners sign renewable electricity agreement
- 10/27/22
- McDonald's: Delivery now in over 100 countries
- 01/06/23
- Southwest reports preliminary Q4 capacity down 6% vs. 4Q19
- 01/06/23
- Southwest canceled more than 16,700 flights from December 21-December 31
- 01/06/23
- Southwest expects to report net loss in Q4
- 01/06/23
- Southwest expects to report net loss in Q4
- $329.32 /
+3.385 (+1.04%) - 12/08/22
- Lululemon falls 9% to $340.75 after Q3 results and guidance
- 12/08/22
- Lululemon reports Q3 SSS up 22% or 25% on constant FX basis
- 10/05/22
- Xponential Fitness debuts workouts on Lululemon Studio
- 09/30/22
- Peloton, Lululemon reach settlement over athletic wear
- 01/04/23
- Luminar Technologies jumps 4% to $4.86 per share after updating production wins
- 01/04/23
- Luminar signed new series production deals for multiple models in December
- 10/02/22
- Fly Intel: Top five weekend stock stories
- 08/08/22
- Luminaris on track to meet or beat 2022 business milestones
- 01/03/23
- Federal regulators issue joint statement on crypto-asset risks to banks
- 01/03/23
- Kentucky lists BlackRock, Citi, JPMorgan as energy boycotters
- 01/03/23
- Great Elm sells majority interest in Forest Investments to JPMorgan affiliate
- 12/14/22
- SEC proposes rules to enhance competition for retail order flow execution
- 01/06/23
- Alkermes reports interim award in arbitration proceedings with Janssen
- 12/22/22
- Steel Dynamics to replace Abiomed in S&P 500 at open on 12/22
- 12/28/22
- HTG Molecular provides highlights of second event in KOL webcast series
- 12/21/22
- HTG Molecular trading resumes
- 12/21/22
- HTG Molecular trading halted, volatility trading pause
- 12/20/22
- HTG Molecular says stock begins trading on Nasdaq Dec. 21 after reverse split
- 01/06/23
- Greenbrier falls -14.0%
- 01/06/23
- Greenbrier falls -13.5%
- 01/06/23
- Greenbrier falls -14.5%
- 01/04/23
- North American rail traffic down 4.3% for the week ending December 31
- 01/05/23
- Fate Therapeutics down 45% on termination of collaboration pact with Janssen
- 01/05/23
- Fate Therapeutics trading resumes
- 01/05/23
- Fate Therapeutics trading halted, news pending
- 12/13/22
- Fate Therapeutics announces data on approaches to cancer immunotherapies
- 01/06/23
- Eisai announces Leqembi U.S. launch pricing at $26,500 per year
- 01/06/23
- Eisai announces Leqembi U.S. launch pricing at $26,500 per year
- 01/06/23
- Biogen, Eisai announce FDA approves Leqembi to treat Alzheimer's disease
- 12/04/22
- Fly Intel: Top five weekend stock stories
- 01/06/23
- CMS says Biogen approval falls under existing national coverage determination
- 01/06/23
- Biogen up 7% to $290.76 after FDA approves Leqembi
- 01/06/23
- Biogen trading resumes
- 01/06/23
- Biogen to resume trading at 3:05 p.m. ET
- 01/06/23
- Baxter to spin off Renal Care and Acute Therapies, form new operating model
- 12/01/22
- Baxter sees some recessionary risk in 2023
- 11/09/22
- Rockwell Medical reacquires distribution rights to hemodialysis concentrates
- 09/07/22
- Baxter CFO: Seeing 'stable to improving levels' in many areas
- 12/18/22
- Fly Intel: Top five weekend stock stories
- 12/09/22
- BofA CEO says headcount management 'won't take layoffs'
- 12/09/22
- BofA CEO, asked about Treasury 'short list' report, says has 'best job in world'
AUPH Aurinia Pharmaceuticals - 01/03/23
- Aurinia Pharmaceuticals enters patent settlement pact with Sun Pharmaceutical
- 11/30/22
- Aurinia announces U.K. marketing authorization of Lupkynis
- 09/19/22
- Aurinia announces European Commission approval of LUPKYNIS
- 07/26/22
- Aurinia says USPTO to institute trial on Inter Partes review of Lupkynis patent
- 01/06/23
- Atai Life Sciences says Phase 2a trial of PCN-101 did not meet primary endpoint
- 12/23/22
- Atai Life Sciences reports results from Phase 1 trial of KUR-101
- 12/19/22
- Atai Life Sciences initiates Phase 2b proof-of-concept trial of RL-007
- 11/29/22
- Atai Life Sciences names Sahil Kirpekar Chief Business Officer
- 01/03/23
- Amarin in patent infringement settlement with Health Net, no terms
- 12/07/22
- Amarin announces VAZKEPA receives regulatory approval in Switzerland
- 11/15/22
- Amarin announces VAZKEPA approved by TGA in Australia
- 11/07/22
- HLS Therapeutics highlights data on RESPECT-EPA study
- $1.29 /
+0.2974 (+29.96%) - 01/05/23
- Aligos on track to complete Phase 2-enabling activities in 2023 for ALG-055009
- 12/14/22
- Aligos Therapeutics initiates dosing in ALG-125755 trial
- 12/08/22
- Aligos presents nonclinical data for coronavirus therapeutic program
- 11/04/22
- Aligos Therapeutics presents data for its Capsid Assembly Modulator
- $22.80 /
+5.555 (+32.21%) - 01/05/23
- Aehr Test Systems jumps 14% after Q2 earnings beat, production order
- 01/05/23
- Aehr Test Systems announces follow on order from silicon carbide chip client
- 12/07/22
- Aehr Test Systems receives inital production order for FOX-XP multi-wafer test
- 11/04/22
- Aehr Test Systems receives over $4M in orders for FOX WaferPak
- 12/16/22 Goldman Sachs
- Southwest resumed with a Neutral at Goldman Sachs
- 12/15/22 Cowen
- Copa Holdings upgraded to Outperform at Cowen amid airlines rating shake-up
- 12/08/22 Susquehanna
- Southwest guidance suggests risk around order book, says Susquehanna
- 12/08/22 Deutsche Bank
- Southwest price target raised to $62 from $60 at Deutsche Bank
- 01/06/23 Morgan Stanley
- Baxter downgraded to Equal Weight from Overweight at Morgan Stanley
- 01/05/23 Raymond James
- Baxter downgraded to Market Perform from Outperform at Raymond James
- 01/04/23 Barclays
- Baxter price target lowered to $63 from $64 at Barclays
- 01/03/23 BofA
- BofA downgrades Baxter to Neutral, prefers Becton Dickinson
- 01/06/23 Loop Capital
- WWE price target raised to $105 from $90 at Loop Capital
- 01/06/23 MKM Partners
- MKM Partners sees WWE as 'very attractive asset' if it goes for sale
- 11/29/22 Morgan Stanley
- WWE price target raised to $80 from $75 at Morgan Stanley
- 10/19/22 MKM Partners
- WWE price target raised to $90 from $84 at MKM Partners
- 01/05/23 Oppenheimer
- Oppenheimer downgrades Wendy's, reveals top 2023 restaurant picks
- 01/05/23 Deutsche Bank
- McDonald's price target raised to $263 from $262 at Deutsche Bank
- 01/05/23 Barclays
- McDonald's price target raised to $310 from $295 at Barclays
- 12/21/22 Jefferies
- McDonald's price target raised to $315 from $305 at Jefferies
- 01/05/23 RBC Capital
- RBC says hotline sign of possible imminent approval for Biogen
- 12/02/22 JonesResearch
- Anavex price target raised to $80 from $40 at JonesTrading
- 12/01/22 Atlantic Equities
- Biogen price target raised to $295 from $220 at Atlantic Equities
- 11/30/22 Mizuho
- Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
- 11/30/22 Jefferies
- Biogen price target raised to $350 from $325 at Jefferies
- 11/29/22 Jefferies
- Prothena data from AD/PD abstract 'promising,' says Jefferies
- 01/06/23 Deutsche Bank
- JPMorgan downgraded to Hold with $145 target at Deutsche Bank
- 01/06/23 Deutsche Bank
- JPMorgan downgraded to Hold from Buy at Deutsche Bank
- 01/03/23 Barclays
- JPMorgan price target raised to $189 from $162 at Barclays
- 12/28/22 Oppenheimer
- JPMorgan price target lowered to $169 from $174 at Oppenheimer
- 01/06/23 Deutsche Bank
- Bank of America downgraded to Hold with $36 target at Deutsche Bank
- 01/06/23 Deutsche Bank
- Bank of America downgraded to Hold from Buy at Deutsche Bank
- 01/03/23 Barclays
- Bank of America price target lowered to $48 from $51 at Barclays
- 12/28/22 Oppenheimer
- Bank of America price target lowered to $51 from $52 at Oppenheimer
- $329.32 /
+3.385 (+1.04%) - 01/06/23 Wells Fargo
- Lululemon upgraded to Overweight from Equal Weight at Wells Fargo
- 01/06/23 Wells Fargo
- Lululemon upgraded to Overweight from Equal Weight at Wells Fargo
- 01/05/23 Piper Sandler
- Lululemon price target lowered to $385 from $390 at Piper Sandler
- 12/12/22 Argus
- Lululemon selloff presents buying opportunity, says Argus
- $1.29 /
+0.2974 (+29.96%) - 01/06/23 Piper Sandler
- Aligos upgraded to Overweight at Piper after peer's 'highly encouraging' data
- 01/06/23 Piper Sandler
- Aligos Therapeutics upgraded to Overweight from Neutral at Piper Sandler
- 01/06/23 Jefferies
- Jefferies upgrades Aligos to Buy on derisking of NASH pill
- 01/06/23 Jefferies
- Aligos Therapeutics upgraded to Buy from Hold at Jefferies
- 01/06/23 Wells Fargo
- Ulta Beauty downgraded to Underweight from Equal Weight at Wells Fargo
- 01/06/23 Wells Fargo
- Ulta Beauty downgraded to Underweight from Equal Weight at Wells Fargo
- 01/05/23 Argus
- Ulta Beauty price target raised to $530 from $455 at Argus
- 12/12/22 Goldman Sachs
- Ulta Beauty downgraded to Neutral from Buy at Goldman Sachs
- 01/06/23 Craig-Hallum
- Silvergate Capital downgraded to Hold from Buy at Craig-Hallum
- 01/06/23 BofA
- BofA downgrades Silvergate to Underperform with 'more questions than answers'
- 01/06/23 BofA
- Silvergate Capital downgraded to Underperform from Neutral at BofA
- 01/06/23 Canaccord
- Silvergate Capital price target lowered to $25 from $150 at Canaccord
- $113.01 /
+2.635 (+2.39%) - 01/06/23 Piper Sandler
- Piper 'unsurprised' by Tesla decision to cut prices in China
- 01/06/23 BofA
- XPeng downgraded to Neutral at BofA after Tesla price cuts
- 01/06/23 GLJ Research
- Tesla price cuts in China 'much worse than you think,' says GLJ Research
- 01/05/23 Edward Jones
- Edward Jones upgrades Tesla on long-term growth opportunities
- 12/20/22 JPMorgan
- Luminar price target lowered to $16 from $30 at JPMorgan
- 12/07/22 Citi
- Luminar price target lowered to $20 from $21 at Citi
- 11/16/22 Berenberg
- Berenberg says top LiDAR idea Innoviz Technologies undervalued
- 11/01/22 WestPark Capital
- Luminar initiated with a Buy at WestPark Capital
- 12/16/22 Barclays
- Bunzl downgraded to Underweight from Equal Weight at Barclays
- 11/14/22 Credit Suisse
- Bunzl assumed with a Neutral at Credit Suisse
- 08/31/22 JPMorgan
- Bunzl price target raised to 3,250 GBp from 3,200 GBp at JPMorgan
- 08/19/22 Jefferies
- Bunzl downgraded to Hold from Buy at Jefferies
RTX Raytheon Technologies - 12/08/22 Citi
- Raytheon Technologies initiated with a Neutral at Citi
- 11/28/22 Cowen
- Raytheon Technologies a Best Idea for 2023, says Cowen
- 10/26/22 Morgan Stanley
- Raytheon Technologies price target lowered to $119 from $124 at Morgan Stanley
- 10/26/22 Baird
- Raytheon Technologies price target lowered to $106 from $117 at Baird
- $50.91 /
+1.2548 (+2.53%) - 01/05/23 Morgan Stanley
- Morgan Stanley sees Moderna's phase 3 RSV vaccine data as catalyst-driven idea
- 01/04/23 BofA
- BioMarin price target raised to $200, added to 'US 1 List' at BofA
- 01/04/23 BofA
- Pfizer downgraded to Neutral at BofA on COVID-19 uncertainty
- 01/04/23 BofA
- Pfizer downgraded to Neutral from Buy at BofA
- $22.80 /
+5.555 (+32.21%) - 10/17/22 William Blair
- Aehr Test Systems initiated with an Outperform at William Blair
- 01/06/23 Jefferies
- Jefferies upgrades 'intriguing small cap value play' Amarin to Buy
- 01/06/23 Jefferies
- Amarin upgraded to Buy from Hold at Jefferies
- 05/06/22 JPMorgan
- JPMorgan downgrades Amarin to sell on headwinds in U.S., Europe
- 05/06/22 JPMorgan
- Amarin downgraded to Underweight from Neutral at JPMorgan
- 01/06/23 Truist
- Truist cuts Fate Therapeutics to Hold after discontinuing Janssen collaboration
- 01/06/23 BofA
- Fate Therapeutics double downgraded to Underperform at BofA
- 01/06/23 BofA
- Fate Therapeutics downgraded to Underperform from Buy at BofA
- 01/06/23 Wedbush
- Fate Therapeutics downgraded to Neutral from Outperform at Wedbush
- 01/06/23 BMO Capital
- Fate Therapeutics downgraded to Market Perform from Outperform at BMO Capital
- 01/03/23 Wells Fargo
- Wells Fargo upgrades Immunovant to Overweight, raises price target to $27
- 01/06/23 EF Hutton
- Atai Life Sciences price target lowered to $15 from $23 at EF Hutton
- 12/15/22 EF Hutton
- Atai Life Sciences initiated with a Buy at EF Hutton
- 11/01/22 Loop Capital
- Atai Life Sciences initiated with a Buy at Loop Capital
- 09/01/22 Citi
- Atai Life Sciences price target lowered to $20 from $22 at Citi
- 01/06/23 BofA
- XPeng downgraded to Neutral from Buy at BofA
- 01/04/23 Wedbush
- Demand issues, Twitter focus creates 'perfect storm' for Tesla, says Wedbush
- 12/14/22 Daiwa
- Daiwa downgrades XPeng to Sell from Buy on 'weakened competitiveness'
- 01/06/23 BofA
- Boot Barn initiated with a Buy, $85 price target at BofA
- 01/06/23 BofA
- Boot Barn initiated with a Buy at BofA
- 01/04/23 Citi
- Citi ups Boot Barn target, expects positive preannouncement
- 01/03/23 JPMorgan
- Boot Barn price target raised to $94 from $92 at JPMorgan
- 12/29/22 H.C. Wainwright
- H.C. Wainwright institutes $15 price target on HTG Molecular shares
- 07/22/22 Cantor Fitzgerald
- HTG Molecular price target lowered to $3.50 from $15 at Cantor Fitzgerald
- 05/16/22 H.C. Wainwright
- HTG Molecular price target lowered to $3 from $4 at H.C. Wainwright
- 03/30/22 H.C. Wainwright
- HTG Molecular price target lowered to $4 from $9 at H.C. Wainwright
- 11/07/22 Susquehanna
- Greenbrier downgraded to Neutral from Positive at Susquehanna
- 07/13/22 Cowen
- Greenbrier price target lowered to $47 from $54
- 07/12/22 Susquehanna
- Greenbrier price target lowered to $38 from $58 at Susquehanna
- 07/11/22 BofA
- Greenbrier downgraded to Neutral at BofA after Q3 earnings miss
AUPH Aurinia Pharmaceuticals - 01/03/23 RBC Capital
- Aurinia price target raised to $11 from $10 at RBC Capital
- 11/07/22 H.C. Wainwright
- Aurinia Pharmaceuticals price target lowered to $14 from $26 at H.C. Wainwright
- 11/04/22 Oppenheimer
- Oppenheimer downgrades Aurinia on commercial challenges
- 11/04/22 Oppenheimer
- Aurinia Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
- 11/25/22 William Blair
- Report about Galaxy S23 'significant positive' for Iridium, says William Blair
- 08/22/22 Loop Capital
- Enovix price target raised to $100 from $50 at Loop Capital
- 08/11/22 Loop Capital
- Loop Capital has 'stronger conviction' in Enovix after 'customer milestones'
- 06/22/22 Loop Capital
- Samsung initiated with a Buy at Loop Capital
- 11/30/22
- XPeng sees Q4 revenue RMB 4.8B-RMB 5.1B
- 11/30/22
- XPeng reports Q3 EPS (36c), consensus (36c)
- 08/23/22
- XPeng sees Q3 revenue RMB6.8B-RMB7.2B, up 18.9%-25.9% from last year
- 08/23/22
- XPeng reports Q2 no-GAAP EPS (43c), consensus ($2.61)
- 11/02/22
- WWE reports Q3 EPS 49c, consensus 50c
- 08/16/22
- WWE reports Q2 adjusted EPS 59c vs. 34c last year
- 07/25/22
- WWE reports preliminary Q2 revenue $328M, consensus $311.84M
- 12/01/22
- Ulta Beauty raises FY22 EPS view to $22.60-$22.90 from $20.70-$21.20
- 12/01/22
- Ulta Beauty raises FY22 revenue view to $9.95B-$10.0B from $9.65B-$9.75B
- 12/01/22
- Ulta Beauty reports Q3 EPS $5.34, consensus $4.15
- 12/01/22
- Notable companies reporting after market close
- $113.01 /
+2.635 (+2.39%) - 10/19/22
- Tesla reports Q3 EPS $1.05, consensus 99c
- 10/19/22
- Notable companies reporting after market close
- 07/20/22
- Tesla reports Q2 EPS $2.27, consensus $1.85
- 07/20/22
- Notable companies reporting after market close
- 01/05/23
- Samsung sees Q4 operating profit KRW4.30T vs. KRW6.65T consensus
- 10/26/22
- Samsung reports Q3 net profit KRW 9.39T vs. KRW 12.29T last year
- 10/06/22
- Samsung sees Q3 operating profit KRW10.8T vs. KRW12.1T consensus
- 07/28/22
- Samsung reports Q2 EPS KRW 1,613 vs. KRW 1,391 last year
- 10/18/22
- Silvergate Capital reports Q3 EPS $1.28, consensus $1.38
- 07/19/22
- Silvergate Capital reports Q2 EPS $1.13, consensus 84c
- 07/18/22
- Notable companies reporting before tomorrow's open
RTX Raytheon Technologies - 10/25/22
- Raytheon Technologies ups FY22 adjusted EPS view to $4.70-$4.80 from $4.60-$4.80
- 10/25/22
- Raytheon Technologies reports Q3 adjusted EPS $1.21, consensus $1.14
- $50.91 /
+1.2548 (+2.53%) - 11/01/22
- Pfizer raises FY22 adjusted EPS view to $6.40-$6.50 from $6.30-$6.45
- 11/01/22
- Pfizer reports Q3 adjusted EPS $1.78, consensus $1.39
- 10/31/22
- Notable companies reporting before tomorrow's open
- 10/27/22
- McDonald's reports Q3 adjusted EPS $2.68, consensus $2.58
- 07/26/22
- McDonald's reports Q2 adjusted EPS $2.55, consensus $2.47
- 10/27/22
- Southwest sees FY22 ASMs down 4.5%
- 10/27/22
- Southwest sees Q4 revenue up 13%-17%, consensus $6.23B
- 10/27/22
- Southwest reports Q3 adjusted EPS 50c, consensus 42c
- 10/26/22
- Notable companies reporting before tomorrow's open
- $329.32 /
+3.385 (+1.04%) - 12/08/22
- Lululemon sees FY22 EPS $9.87-$9.97, consensus $9.92
- 12/08/22
- Lululemon sees Q4 EPS $4.20-$4.30, consensus $4.30
- 12/08/22
- Lululemon reports Q3 EPS $2.00, consensus $1.97
- 12/08/22
- Notable companies reporting after market close
- 11/02/22
- Luminar reports Q3 EPS (18c), consensus (20c)
- 11/02/22
- Notable companies reporting after market close
- 08/08/22
- Luminar reports Q2 adjusted EPS (18c), consensus (16c)
- 08/08/22
- Notable companies reporting after market close
- 10/14/22
- JPMorgan reports Q3 EPS $3.12, consensus $2.88
- 10/13/22
- Notable companies reporting before tomorrow's open
- 07/14/22
- JPMorgan reports Q2 EPS $2.76, consensus $2.91
- 10/18/22
- Johnson & Johnson cuts FY22 estimated reported sales view to $93.0B-$93.5B
- 10/18/22
- Johnson & Johnson narrows FY22 adjusted operational EPS view to $10.70-$10.75
- 10/18/22
- Johnson & Johnson narrows FY22 adjusted EPS view to $10.02-$10.07
- 10/18/22
- Johnson & Johnson reports Q3 adjusted EPS $2.55, consensus $2.48
- 01/06/23
- HTG Molecular reports preliminary 2022 revenue $6.4M, two est. $5.7M
- 01/06/23
- Greenbrier reports Q1 adjusted EPS 5c, consensus 50c
- 10/27/22
- Greenbrier sees FY23 revenue $3.2B-$3.6B, consensus $3.03B
- 10/27/22
- Greenbrier reports Q4 EPS 60c, consensus 42c
- 07/11/22
- Greenbrier reports Q3 EPS 9c, consensus 59c
- 11/03/22
- Fate Therapeutics reports Q3 EPS (86c), consensus (89c)
- 08/03/22
- Fate Therapeutics reports Q2 EPS (79c), consensus (83c)
- 01/06/23
- Boot Barn reports preliminary Q3 EPS $1.74, consensus $1.78
- 10/26/22
- Boot Barn cuts FY23 EPS view to $5.70-$5.90 from $6-$6.20, consensus $5.90
- 10/26/22
- Boot Barn sees Q3 EPS $1.71-$1.83, consensus $2.09
- 10/26/22
- Boot Barn Holdings reports Q2 EPS $1.06, consensus 90c
- 10/25/22
- Biogen raises FY22 EPS view to $16.50-$17.15, consensus $16.49
- 10/25/22
- Biogen reports Q3 adjusted EPS $4.77, consensus $4.15
- 10/24/22
- Notable companies reporting before tomorrow's open
- 10/27/22
- Baxter sees FY22 EPS $3.53- $3.60, consensus $3.62
- 10/27/22
- Baxter sees FY22 revenue growth of 17%-18%, consensus $15.02B
- 10/27/22
- Baxter sees FY22 EPS $3.53- $3.60, consensus $3.62
- 10/27/22
- Baxter reports Q2 EPS 82c, consensus 81c
- 10/17/22
- Bank of America reports Q3 EPS 81c, consensus 77c
- 07/18/22
- Bank of America reports Q2 EPS 73c, consensus 78c
AUPH Aurinia Pharmaceuticals - 01/06/23
- Aurinia Pharmaceuticals backs FY23 net product revenue view $120M-$140M
- 01/06/23
- Aurinia Pharmaceuticals reports preliminary net FY22 revenue $134M
- 01/06/23
- Aurinia Pharmaceuticals reports preliminary Q4 revenue $28.4M, consensus $26.97M
- 11/03/22
- Aurinia Pharmaceuticals lowers FY22 revenue view to $100M-105M from $115M-$135M
- 11/10/22
- Atai Life Sciences reports Q3 EPS (22c), consensus (23c)
- 08/15/22
- Atai Life Sciences reports Q2 EPS (24c) vs. (37c) last year
- 10/27/22
- Amarin continuing to suspend 2022 revenue guidance
- 10/27/22
- Amarin reports Q3 adjusted EPS 2c, consensus (6c)
- 08/03/22
- Amarin reports Q2 adjusted EPS (9c), consensus (6c)
- $1.29 /
+0.2974 (+29.96%) - 11/02/22
- Aligos Therapeutics reports Q3 EPS (44c), consensus (58c)
- $22.80 /
+5.555 (+32.21%) - 01/05/23
- Aehr Test Systems reports Q2 EPS 16c, consensus 8c
- 10/06/22
- Aehr Test Systems backs FY23 revenue view $60M-$70M
- 10/06/22
- Aehr Test Systems reports Q1 EPS 5c vs. (2c) last year
- 07/19/22
- Aehr Test Systems reports Q4 EPS 23c vs. 4c in Q4 last year
- 01/05/23
- Vince McMahon plans to return to WWE to pursue sale, WSJ reports
- 12/13/22
- Vince McMahon faces new demands over assault allegations, WSJ reports
- 11/02/22
- WWE ends probe into alleged misconduct by Vince McMahon, CNBC reports
- 08/17/22
- WWE board finds former CEO McMahon gave $5M to Trump charity, WSJ says
- $113.01 /
+2.635 (+2.39%) - 01/06/23
- Tesla cuts Model 3, Model Y prices in China after delivery slump, WSJ reports
- 01/04/23
- Tesla files trademark for electric motors 'not for land vehicles,' Electrek says
- 01/03/23
- Tom Zhu becomes Tesla's highest profile executive after Musk, Reuters reports
- 01/03/23
- Tesla fined $2.2M in Korea for violations of advertising law, Bloomberg reports
- 01/05/23
- Samsung's profit could plunge nearly 50% in Q4, CNBC reports
- 01/05/23
- Samsung consumer-gadgets chief tells WSJ he expects tech slump to persist
- 12/28/22
- Samsung expected to start memory price cuts in 2023, DigiTimes reports
- 12/15/22
- Samsung Galaxy S23 to adopt customized AP from Qualcomm, DigiTimes reports
- 01/05/23
- Silvergate Capital has laid off 40% of its staff, WSJ reports
- 12/06/22
- US Senators request information on Silvergate dealings with FTX, NBC reports
- 11/19/22
- Crypto's survival may now depend on Washington, Barron's says
- 11/09/22
- SEC expands probe into FTX, WSJ reports
RTX Raytheon Technologies - 01/06/23
- McCarthy's speaker deal includes $75B defense cut, Bloomberg reports
- 01/05/23
- Raytheon weighs sale of actuation unit, Bloomberg reports
- 01/05/23
- Raytheon weighs sale of actuation unit, Bloomberg reports
- 01/04/23
- Lagging arms production raises concerns over industry consolidation, WSJ report
- $50.91 /
+1.2548 (+2.53%) - 01/06/23
- Pfizer in talks to license Chinese drugmakers for generic Paxlovid, Reuters says
- 12/24/22
- Pfizer, Moderna among vaccine makers to watch in 2023, Barron's says
- 12/14/22
- Warren, Welch tell Pfizer to 'back off' price hike for vaccine, STATNews says
- 12/06/22
- Pfizer dismisses Moderna claim it copied COVID-19 shot, CNBC reports
- 01/06/23
- McDonald's to accelerate pace of new restaurant openings, FT reports
- 12/30/22
- Restaurant coalition sues to stop California fast-food wage law, WSJ says
- 10/18/22
- McDonald's to sell Krispy Kreme doughnuts, Restaurant Business reports
- 10/04/22
- McDonald's beats back lawsuit from Black franchisees, Reuters says
- 01/06/23
- Southwest meltdown could cost hundreds of millions of dollars, NY Times reports
- 01/05/23
- Southwest to update earnings guidance before Q4 report, Bloomberg says
- 01/05/23
- Southwest to update earnings guidance before Q4 report, Bloomberg says
- 01/04/23
- Southwest offers 25,000 points to travel meltdown-impacted fliers, WSJ reports
- $329.32 /
+3.385 (+1.04%) - 09/30/22
- Peloton tells Bloomberg resolved dispute with Lululemon over athletic wear
- 09/29/22
- Peloton suit against Lululemon thrown out by court, Bloomberg reports
- 09/29/22
- Lululemon wins dismissal of patent suit by Peloton, Bloomberg reports
- 08/17/22
- Lululemon D.C. workers withdraw bid for union vote, Bloomberg reports
- 01/06/23
- Luminar falls after Citron sees shares heading below $1
- 01/06/23
- Luminar shares heading to under $1, Citron Research says
- 10/01/22
- SPAC bubble has burst, Blue Owl Luminar still have potential, Barron's says
- 12/18/22
- JPMorgan said to seal deal to acquire 48.5% of Viva Wallet, Bloomberg reports
- 12/02/22
- Wall Street banks consider bonus cuts up to 30%, Bloomberg reports
- 11/28/22
- JPMorgan, others discuss how to reimburse scammed Zelle customers, WSJ reports
- 11/25/22
- JPMorgan, Deutsche sued by Jeffrey Epstein accusers, WSJ reports
- 12/04/22
- J&J says won't make offer for Horizon Therapeutics, Bloomberg reports
- 10/20/22
- CDC panel says COVID shots to be added to regular vaccinations, WSJ says
- 10/20/22
- Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports
- 01/05/23
- Bunzl seen as 'inflation winner', Barrons reports
- 12/03/22
- Tapestry, Saia among small-cap stocks set for big gains, Barron's says
- 12/23/22
- Third trial death tied to Biogen and Eisai Alzheimer's drug, Science reports
- 11/28/22
- Second death linked to Eisai's lecanemab Alzheimer's drug, Science says
- 11/07/22
- Biogen weighing new CEO options after talks with J&J exec hit impasse, STAT says
- 10/28/22
- Investigator in Alzheimer's trial linked lecanemab to patient death, STAT says
- 09/14/22
- Baxter looks to sell renal-care services, hemodialysis units, Bloomberg reports
- 12/17/22
- Amazon, Google among Barron's 10 favorite stocks for 2023
- 12/09/22
- BofA CEO Moynihan on short list to replace Yellen, Gaparino says via Twitter
AUPH Aurinia Pharmaceuticals - 01/04/23
- Aurinia worth 'keeping closer eye on' after settlement, Dealreporter says
- 01/03/23
- Oregon becomes first U.S. state to legalize 'magic' mushrooms, NYT says
- 07/18/22
- New data could have led to different result for Amarin's Vascepa, STAT reports
- 01/03/23
- What You Missed This Week in EVs and Clean Energy
- 12/19/22
- What You Missed This Week in EVs and Clean Energy
- 12/14/22
- What You Missed On Wall Street On Wednesday
- 12/14/22
- What You Missed On Wall Street This Morning
- 01/05/23
- Fly Intel: After-Hours Movers
- 08/18/22
- What You Missed On Wall Street This Morning
- 08/16/22
- What You Missed On Wall Street On Tuesday
- 12/12/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/02/22
- What You Missed On Wall Street On Friday
- 12/02/22
- What You Missed On Wall Street This Morning
- 01/05/23
- What You Missed On Wall Street This Morning
- 01/06/23
- Here's What You Missed in Crypto This Week
- 01/05/23
- What You Missed On Wall Street On Thursday
RTX Raytheon Technologies - 12/13/22
- What You Missed On Wall Street On Tuesday
- 12/08/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/15/22
- What You Missed On Wall Street On Tuesday
- $50.91 /
+1.2548 (+2.53%) - 01/04/23
- What You Missed On Wall Street On Wednesday
- 01/04/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 10/27/22
- What You Missed On Wall Street On Thursday
- 10/27/22
- What You Missed On Wall Street This Morning
- 01/06/23
- What You Missed On Wall Street This Morning
- 01/06/23
- Fly Intel: Pre-market Movers
- 01/04/23
- What You Missed On Wall Street This Morning
- 12/29/22
- What You Missed On Wall Street On Thursday
- $329.32 /
+3.385 (+1.04%) - 12/09/22
- What You Missed On Wall Street On Friday
- 12/09/22
- What You Missed On Wall Street This Morning
- 12/09/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 01/04/23
- Fly Intel: After-Hours Movers
- 10/31/22
- What You Missed This Week in EVs and Clean Energy
- 09/26/22
- What You Missed This Week in EVs and Clean Energy
- 01/03/23
- What You Missed On Wall Street On Tuesday
- 01/03/23
- What You Missed On Wall Street This Morning
- 12/08/22
- Fly Intel: Pre-market Movers
- 12/05/22
- What You Missed On Wall Street On Monday
- 07/11/22
- What You Missed On Wall Street On Monday
- 07/11/22
- What You Missed On Wall Street This Morning
- 09/28/22
- What You Missed On Wall Street On Wednesday
- 09/28/22
- What You Missed On Wall Street This Morning
- 10/26/22
- Fly Intel: After-Hours Movers
- 08/11/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/30/22
- Fly Intel: Pre-market Movers
- 11/28/22
- Fly Intel: Pre-market Movers
- 11/14/22
- What You Missed On Wall Street On Monday
- 10/27/22
- Fly Intel: Pre-market Movers
- 10/18/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 09/14/22
- What You Missed On Wall Street This Morning
- 01/06/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
AUPH Aurinia Pharmaceuticals - 01/05/23
- Biotech Alert: Searches spiking for these stocks today
- 01/06/23
- Rising High: Exclusive talk with cannabinoid market research firm BDSA
- 12/29/22
- Here's What You Missed in Cannabis, Psychedelics This Week
- 12/23/22
- What You Missed On Wall Street On Friday
- 12/23/22
- What You Missed On Wall Street This Morning
- 11/07/22
- What You Missed On Wall Street On Monday
- 11/07/22
- What You Missed On Wall Street This Morning
- 07/18/22
- What You Missed On Wall Street On Monday
- 07/18/22
- What You Missed On Wall Street This Morning
- $22.80 /
+5.555 (+32.21%) - 10/07/22
- What You Missed On Wall Street On Friday
- 10/07/22
- What You Missed On Wall Street This Morning
- 01/04/23
- XPeng call volume above normal and directionally bullish
- 12/06/22
- XPeng call volume above normal and directionally bullish
- 12/06/22
- Largest borrow rate increases among liquid names
- 12/02/22
- Unusually active option classes on open December 2nd
- 12/01/22
- Ulta Beauty options imply 5.0% move in share price post-earnings
- 10/11/22
- Early notable gainers among liquid option names on October 11th
- 08/26/22
- Early notable gainers among liquid option names on August 26th
- 08/25/22
- Ulta Beauty options imply 5.6% move in share price post-earnings
- $113.01 /
+2.635 (+2.39%) - 01/06/23
- Notable open interest changes for January 6th
- 01/05/23
- Notable open interest changes for January 5th
- 01/04/23
- Notable open interest changes for January 4th
- 01/03/23
- Notable open interest changes for January 3rd
- 01/06/23
- Largest borrow rate increases among liquid names
- 01/05/23
- Largest borrow rate increases among liquid names
- 12/21/22
- Largest borrow rate increases among liquid names
- 12/13/22
- Silvergate Capital Corp put volume heavy and directionally bearish
RTX Raytheon Technologies - 10/25/22
- Unusually active option classes on open October 25th
- 10/10/22
- Raytheon Technologies call volume above normal and directionally bullish
- 08/22/22
- Raytheon Technologies call volume above normal and directionally bullish
- $50.91 /
+1.2548 (+2.53%) - 11/14/22
- Pfizer call volume above normal and directionally bullish
- 11/01/22
- Unusually active option classes on open November 1st
- 10/21/22
- Unusually active option classes on open October 21st
- 08/19/22
- Early notable gainers among liquid option names on August 19th
- 10/27/22
- Unusually active option classes on open October 27th
- 10/24/22
- Unusually active option classes on open October 24th
- 07/26/22
- Unusually active option classes on open July 26th
- 12/30/22
- Unusually active option classes on open December 30th
- 12/29/22
- Unusually active option classes on open December 29th
- 12/28/22
- Unusually active option classes on open December 28th
- 12/27/22
- Unusually active option classes on open December 27th
- $329.32 /
+3.385 (+1.04%) - 01/04/23
- Lululemon put volume heavy and directionally bearish
- 12/21/22
- Unusually active option classes on open December 21st
- 12/12/22
- Unusually active option classes on open December 12th
- 12/08/22
- Lululemon options imply 6.9% move in share price post-earnings
- 12/06/22
- Luminar Technologies put volume heavy and directionally bearish
- 11/02/22
- Luminar Technologies options imply 9.1% move in share price post-earnings
- 10/14/22
- Notable open interest changes for October 14th
- 09/28/22
- Notable open interest changes for September 28th
- 12/05/22
- JPMorgan put volume heavy and directionally bearish
- 11/30/22
- JPMorgan put volume heavy and directionally bearish
- 10/14/22
- Early notable gainers among liquid option names on October 14th
- 10/14/22
- Unusually active option classes on open October 14th
- 12/22/22
- Johnson & Johnson put volume heavy and directionally bearish
- 11/11/22
- Johnson & Johnson put volume heavy and directionally bearish
- 10/18/22
- Unusually active option classes on open October 18th
- 09/20/22
- Johnson & Johnson put volume heavy and directionally bearish
- 11/30/22
- Early notable gainers among liquid option names on November 30th
- 11/14/22
- Early notable gainers among liquid option names on November 14th
- 10/13/22
- Early notable gainers among liquid option names on October 13th
- 09/29/22
- Unusually active option classes on open September 29th
- 01/05/23
- Baxter call volume above normal and directionally bullish
- 12/14/22
- Baxter put volume heavy and directionally bearish
- 08/31/22
- Early notable gainers among liquid option names on August 31st
- 01/03/23
- Bank of America call volume above normal and directionally bullish
- 12/07/22
- Notable open interest changes for December 7th
- 12/06/22
- Notable open interest changes for December 6th
- 11/07/22
- Bank of America call volume above normal and directionally bullish
AUPH Aurinia Pharmaceuticals - 01/06/23
- Aurinia Pharmaceuticals call volume above normal and directionally bullish
- 07/27/22
- Aurinia Pharmaceuticals call volume above normal and directionally bullish
- $22.80 /
+5.555 (+32.21%) - 01/05/23
- Aehr Test Systems options imply 9.5% move in share price post-earnings
- 11/07/22
- Aehr Test Systems call volume above normal and directionally bullish
- 10/06/22
- Aehr Test Systems options imply 9.5% move in share price post-earnings
|
On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< - $88.13 /
+16.08 (+22.32%) - 01/06/23
- WWE rises 22.2%
- 01/06/23
- WWE trading resumes
- 01/06/23
- WWE says Vince McMahon returning to board, to undertake review of alternatives
- 01/06/23
- WWE to undertake review of strategic alternatives
WBD Warner Bros. Discovery - 01/03/23
- Warner Bros. Discovery enters audience measurement agreement with VideoAmp
- 01/02/23
- Fly Intel: Top five weekend stock stories
- 12/14/22
- Warner Bros.' game 'Hogwarts Legacy' to launch on Switch July 25, 2023
- 12/06/22
- Warner Bros. Discovery, Amazon.com: HBO Max available on Prime Video in U.S.
- 12/05/22
- Ulta Beauty CEO: Consumer is loving what we are offering
- 12/01/22
- Ulta Beauty reports SSS up 14.6% y/y
- 10/07/22
- Tanger Factory announces first Ulta Beauty store opening in Rehoboth Beach
- 09/07/22
- Jeld-Wen appoints Halligan to board of directors
- 01/04/23
- Cathie Wood's ARK Investment bought 21K shares of Tesla today
- 01/03/23
- Cathie Wood's ARK Investment bought 176K shares of Tesla today
- 01/03/23
- Piedmont Lithium jumps 9% to $47.99 after amended pact with Tesla
- 01/03/23
- Piedmont Lithium amends agreement with Tesla
- 01/05/23
- Adeia enters long-term IP license renewal with Samsung Electronics
- 01/03/23
- InterDigital and Samsung to renew license agreement
- 12/22/22
- Stingray Group launches TV channels on Amazon Freevee, Samsung TV Plus
- 12/16/22
- Netlist announces claim construction order against Samsung
- 01/05/23
- Silvergate Capital falls -46.5%
- 01/05/23
- Silvergate Capital falls -43.6%
- 01/05/23
- Silvergate Capital falls -39.0%
- 01/05/23
- Silvergate not seeing clients closing accounts, but taking pause in crypto
RTX Raytheon Technologies - 01/05/23
- Raytheon Technologies awarded $208.7M U.S. Navy contract
- 12/22/22
- Raytheon Technologies awarded $317.42M Navy contract modification
- 12/21/22
- Raytheon Technologies awarded $412.6M Air Force contract
- 12/16/22
- Raytheon Technologies awarded $171.19M Navy contract modification
- 01/06/23
- Pfizer: FDA accepts for priority review sBLA for 20vPnC
- 01/05/23
- 3D Systems appoints Bruce to Medical Advisory Board
- 12/29/22
- Pfizer discloses 5.38M share stake in Oric Pharmaceuticals
- 12/29/22
- Pfizer announces topline results from Phase 3 study of fidanacogene elaparvovec
MDGL Madrigal Pharmaceuticals - 01/06/23
- Madrigal announces additional results from Phase 2 MAESTRO-NASH trial
- 12/19/22
- Viking Therapeutics up 58% after Madrigal announces NASH trial data
- 12/19/22
- Madrigal jumps 217% to $202.28 after NASH study hits endpoints
- 12/19/22
- Madrigal Pharmaceuticals announces results from Phase 3 MAESTRO-NASH trial
- 01/06/23
- Southwest reports preliminary Q4 capacity down 6% vs. 4Q19
- 01/06/23
- Southwest canceled more than 16,700 flights from December 21-December 31
- 01/06/23
- Southwest expects to report net loss in Q4
- 01/06/23
- Southwest expects to report net loss in Q4
- $330.17 /
+4.235 (+1.30%) - 12/08/22
- Lululemon falls 9% to $340.75 after Q3 results and guidance
- 12/08/22
- Lululemon reports Q3 SSS up 22% or 25% on constant FX basis
- 10/05/22
- Xponential Fitness debuts workouts on Lululemon Studio
- 09/30/22
- Peloton, Lululemon reach settlement over athletic wear
- 01/04/23
- Luminar Technologies jumps 4% to $4.86 per share after updating production wins
- 01/04/23
- Luminar signed new series production deals for multiple models in December
- 10/02/22
- Fly Intel: Top five weekend stock stories
- 08/08/22
- Luminaris on track to meet or beat 2022 business milestones
- 01/03/23
- Federal regulators issue joint statement on crypto-asset risks to banks
- 01/03/23
- Kentucky lists BlackRock, Citi, JPMorgan as energy boycotters
- 01/03/23
- Great Elm sells majority interest in Forest Investments to JPMorgan affiliate
- 12/14/22
- SEC proposes rules to enhance competition for retail order flow execution
- 01/06/23
- Alkermes reports interim award in arbitration proceedings with Janssen
- 12/22/22
- Steel Dynamics to replace Abiomed in S&P 500 at open on 12/22
- 12/28/22
- HTG Molecular provides highlights of second event in KOL webcast series
- 12/21/22
- HTG Molecular trading resumes
- 12/21/22
- HTG Molecular trading halted, volatility trading pause
- 12/20/22
- HTG Molecular says stock begins trading on Nasdaq Dec. 21 after reverse split
- 01/06/23
- Greenbrier falls -14.0%
- 01/06/23
- Greenbrier falls -13.5%
- 01/06/23
- Greenbrier falls -14.5%
- 01/04/23
- North American rail traffic down 4.3% for the week ending December 31
- 01/05/23
- Fate Therapeutics down 45% on termination of collaboration pact with Janssen
- 01/05/23
- Fate Therapeutics trading resumes
- 01/05/23
- Fate Therapeutics trading halted, news pending
- 12/13/22
- Fate Therapeutics announces data on approaches to cancer immunotherapies
- 12/04/22
- Fly Intel: Top five weekend stock stories
- 01/06/23
- Baxter to spin off Renal Care and Acute Therapies, form new operating model
- 12/01/22
- Baxter sees some recessionary risk in 2023
- 11/09/22
- Rockwell Medical reacquires distribution rights to hemodialysis concentrates
- 09/07/22
- Baxter CFO: Seeing 'stable to improving levels' in many areas
- 12/18/22
- Fly Intel: Top five weekend stock stories
- 12/09/22
- BofA CEO says headcount management 'won't take layoffs'
- 12/09/22
- BofA CEO, asked about Treasury 'short list' report, says has 'best job in world'
AUPH Aurinia Pharmaceuticals - 01/03/23
- Aurinia Pharmaceuticals enters patent settlement pact with Sun Pharmaceutical
- 11/30/22
- Aurinia announces U.K. marketing authorization of Lupkynis
- 09/19/22
- Aurinia announces European Commission approval of LUPKYNIS
- 07/26/22
- Aurinia says USPTO to institute trial on Inter Partes review of Lupkynis patent
- $1.19 /
+0.1974 (+19.89%) - 01/05/23
- Aligos on track to complete Phase 2-enabling activities in 2023 for ALG-055009
- 12/14/22
- Aligos Therapeutics initiates dosing in ALG-125755 trial
- 12/08/22
- Aligos presents nonclinical data for coronavirus therapeutic program
- 11/04/22
- Aligos Therapeutics presents data for its Capsid Assembly Modulator
- 12/16/22 Goldman Sachs
- Southwest resumed with a Neutral at Goldman Sachs
- 12/15/22 Cowen
- Copa Holdings upgraded to Outperform at Cowen amid airlines rating shake-up
- 12/08/22 Susquehanna
- Southwest guidance suggests risk around order book, says Susquehanna
- 12/08/22 Deutsche Bank
- Southwest price target raised to $62 from $60 at Deutsche Bank
- 01/06/23 Morgan Stanley
- Baxter downgraded to Equal Weight from Overweight at Morgan Stanley
- 01/05/23 Raymond James
- Baxter downgraded to Market Perform from Outperform at Raymond James
- 01/04/23 Barclays
- Baxter price target lowered to $63 from $64 at Barclays
- 01/03/23 BofA
- BofA downgrades Baxter to Neutral, prefers Becton Dickinson
- $88.13 /
+16.08 (+22.32%) - 01/06/23 Loop Capital
- WWE price target raised to $105 from $90 at Loop Capital
- 01/06/23 MKM Partners
- MKM Partners sees WWE as 'very attractive asset' if it goes for sale
- 11/29/22 Morgan Stanley
- WWE price target raised to $80 from $75 at Morgan Stanley
- 10/19/22 MKM Partners
- WWE price target raised to $90 from $84 at MKM Partners
- 01/06/23 BofA
- XPeng downgraded to Neutral at BofA after Tesla price cuts
- 01/06/23 GLJ Research
- Tesla price cuts in China 'much worse than you think,' says GLJ Research
- 01/05/23 Edward Jones
- Edward Jones upgrades Tesla on long-term growth opportunities
- 01/05/23 Edward Jones
- Tesla upgraded to Buy from Hold at Edward Jones
- 01/06/23 Truist
- Truist cuts Fate Therapeutics to Hold after discontinuing Janssen collaboration
- 01/06/23 BofA
- Fate Therapeutics double downgraded to Underperform at BofA
- 01/06/23 BofA
- Fate Therapeutics downgraded to Underperform from Buy at BofA
- 01/06/23 Wedbush
- Fate Therapeutics downgraded to Neutral from Outperform at Wedbush
- 01/06/23 BMO Capital
- Fate Therapeutics downgraded to Market Perform from Outperform at BMO Capital
- 01/03/23 Wells Fargo
- Wells Fargo upgrades Immunovant to Overweight, raises price target to $27
- 12/20/22 JPMorgan
- Luminar price target lowered to $16 from $30 at JPMorgan
- 12/07/22 Citi
- Luminar price target lowered to $20 from $21 at Citi
- 11/16/22 Berenberg
- Berenberg says top LiDAR idea Innoviz Technologies undervalued
- 11/01/22 WestPark Capital
- Luminar initiated with a Buy at WestPark Capital
WBD Warner Bros. Discovery - 01/04/23 Macquarie
- Warner Bros. Discovery price target lowered to $16 from $18 at Macquarie
- 12/07/22 BofA
- Warner Bros. Discovery the 'best value in media,' says BofA
- 11/14/22 Spin-Off Research
- Warner Bros. Discovery downgraded to Hold from Buy at Spin-Off Research
- 11/10/22 Citi
- Warner Bros. Discovery price target lowered to $18 from $21 at Citi
- 12/16/22 Barclays
- Bunzl downgraded to Underweight from Equal Weight at Barclays
- 11/14/22 Credit Suisse
- Bunzl assumed with a Neutral at Credit Suisse
- 08/31/22 JPMorgan
- Bunzl price target raised to 3,250 GBp from 3,200 GBp at JPMorgan
- 08/19/22 Jefferies
- Bunzl downgraded to Hold from Buy at Jefferies
RTX Raytheon Technologies - 12/08/22 Citi
- Raytheon Technologies initiated with a Neutral at Citi
- 11/28/22 Cowen
- Raytheon Technologies a Best Idea for 2023, says Cowen
- 10/26/22 Morgan Stanley
- Raytheon Technologies price target lowered to $119 from $124 at Morgan Stanley
- 10/26/22 Baird
- Raytheon Technologies price target lowered to $106 from $117 at Baird
- 01/06/23 BofA
- Boot Barn initiated with a Buy, $85 price target at BofA
- 01/06/23 BofA
- Boot Barn initiated with a Buy at BofA
- 01/04/23 Citi
- Citi ups Boot Barn target, expects positive preannouncement
- 01/03/23 JPMorgan
- Boot Barn price target raised to $94 from $92 at JPMorgan
- 12/29/22 H.C. Wainwright
- H.C. Wainwright institutes $15 price target on HTG Molecular shares
- 07/22/22 Cantor Fitzgerald
- HTG Molecular price target lowered to $3.50 from $15 at Cantor Fitzgerald
- 05/16/22 H.C. Wainwright
- HTG Molecular price target lowered to $3 from $4 at H.C. Wainwright
- 03/30/22 H.C. Wainwright
- HTG Molecular price target lowered to $4 from $9 at H.C. Wainwright
- 11/07/22 Susquehanna
- Greenbrier downgraded to Neutral from Positive at Susquehanna
- 07/13/22 Cowen
- Greenbrier price target lowered to $47 from $54
- 07/12/22 Susquehanna
- Greenbrier price target lowered to $38 from $58 at Susquehanna
- 07/11/22 BofA
- Greenbrier downgraded to Neutral at BofA after Q3 earnings miss
AUPH Aurinia Pharmaceuticals - 01/03/23 RBC Capital
- Aurinia price target raised to $11 from $10 at RBC Capital
- 11/07/22 H.C. Wainwright
- Aurinia Pharmaceuticals price target lowered to $14 from $26 at H.C. Wainwright
- 11/04/22 Oppenheimer
- Oppenheimer downgrades Aurinia on commercial challenges
- 11/04/22 Oppenheimer
- Aurinia Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
- 11/25/22 William Blair
- Report about Galaxy S23 'significant positive' for Iridium, says William Blair
- 08/22/22 Loop Capital
- Enovix price target raised to $100 from $50 at Loop Capital
- 08/11/22 Loop Capital
- Loop Capital has 'stronger conviction' in Enovix after 'customer milestones'
- 06/22/22 Loop Capital
- Samsung initiated with a Buy at Loop Capital
- 01/06/23 Deutsche Bank
- JPMorgan downgraded to Hold with $145 target at Deutsche Bank
- 01/06/23 Deutsche Bank
- JPMorgan downgraded to Hold from Buy at Deutsche Bank
- 01/03/23 Barclays
- JPMorgan price target raised to $189 from $162 at Barclays
- 12/28/22 Oppenheimer
- JPMorgan price target lowered to $169 from $174 at Oppenheimer
- 01/06/23 Deutsche Bank
- Bank of America downgraded to Hold with $36 target at Deutsche Bank
- 01/06/23 Deutsche Bank
- Bank of America downgraded to Hold from Buy at Deutsche Bank
- 01/03/23 Barclays
- Bank of America price target lowered to $48 from $51 at Barclays
- 12/28/22 Oppenheimer
- Bank of America price target lowered to $51 from $52 at Oppenheimer
- $330.17 /
+4.235 (+1.30%) - 01/06/23 Wells Fargo
- Lululemon upgraded to Overweight from Equal Weight at Wells Fargo
- 01/06/23 Wells Fargo
- Lululemon upgraded to Overweight from Equal Weight at Wells Fargo
- 01/05/23 Piper Sandler
- Lululemon price target lowered to $385 from $390 at Piper Sandler
- 12/12/22 Argus
- Lululemon selloff presents buying opportunity, says Argus
- $1.19 /
+0.1974 (+19.89%) - 01/06/23 Piper Sandler
- Aligos upgraded to Overweight at Piper after peer's 'highly encouraging' data
- 01/06/23 Piper Sandler
- Aligos Therapeutics upgraded to Overweight from Neutral at Piper Sandler
- 01/06/23 Jefferies
- Jefferies upgrades Aligos to Buy on derisking of NASH pill
- 01/06/23 Jefferies
- Aligos Therapeutics upgraded to Buy from Hold at Jefferies
MDGL Madrigal Pharmaceuticals - 01/06/23 Canaccord
- Madrigal Pharmaceuticals price target raised to $296 from $270 at Canaccord
- 01/05/23 JMP Securities
- Madrigal Pharmaceuticals price target raised to $390 from $312 at JMP Securities
- 01/06/23 Wells Fargo
- Ulta Beauty downgraded to Underweight from Equal Weight at Wells Fargo
- 01/06/23 Wells Fargo
- Ulta Beauty downgraded to Underweight from Equal Weight at Wells Fargo
- 01/05/23 Argus
- Ulta Beauty price target raised to $530 from $455 at Argus
- 12/12/22 Goldman Sachs
- Ulta Beauty downgraded to Neutral from Buy at Goldman Sachs
- 01/06/23 Craig-Hallum
- Silvergate Capital downgraded to Hold from Buy at Craig-Hallum
- 01/06/23 BofA
- BofA downgrades Silvergate to Underperform with 'more questions than answers'
- 01/06/23 BofA
- Silvergate Capital downgraded to Underperform from Neutral at BofA
- 01/06/23 Canaccord
- Silvergate Capital price target lowered to $25 from $150 at Canaccord
- 01/05/23 Morgan Stanley
- Morgan Stanley sees Moderna's phase 3 RSV vaccine data as catalyst-driven idea
- 01/04/23 BofA
- BioMarin price target raised to $200, added to 'US 1 List' at BofA
- 01/04/23 BofA
- Pfizer downgraded to Neutral at BofA on COVID-19 uncertainty
- 01/04/23 BofA
- Pfizer downgraded to Neutral from Buy at BofA
- $88.13 /
+16.08 (+22.32%) - 11/02/22
- WWE reports Q3 EPS 49c, consensus 50c
- 08/16/22
- WWE reports Q2 adjusted EPS 59c vs. 34c last year
- 07/25/22
- WWE reports preliminary Q2 revenue $328M, consensus $311.84M
WBD Warner Bros. Discovery - 11/03/22
- Warner Bros. Discovery reports Q3 EPS (95c), consensus (21c)
- 11/03/22
- Warner Bros. Discovery reports Q3 revenue $9.82B, consensus $10.36B
- 11/03/22
- Notable companies reporting after market close
- 08/04/22
- Warner Bros. Discovery cuts FY22 adjusted EBITDA view to $9.0B-$9.5B
- 12/01/22
- Ulta Beauty raises FY22 EPS view to $22.60-$22.90 from $20.70-$21.20
- 12/01/22
- Ulta Beauty raises FY22 revenue view to $9.95B-$10.0B from $9.65B-$9.75B
- 12/01/22
- Ulta Beauty reports Q3 EPS $5.34, consensus $4.15
- 12/01/22
- Notable companies reporting after market close
- 10/19/22
- Tesla reports Q3 EPS $1.05, consensus 99c
- 10/19/22
- Notable companies reporting after market close
- 07/20/22
- Tesla reports Q2 EPS $2.27, consensus $1.85
- 07/20/22
- Notable companies reporting after market close
- 01/05/23
- Samsung sees Q4 operating profit KRW4.30T vs. KRW6.65T consensus
- 10/26/22
- Samsung reports Q3 net profit KRW 9.39T vs. KRW 12.29T last year
- 10/06/22
- Samsung sees Q3 operating profit KRW10.8T vs. KRW12.1T consensus
- 07/28/22
- Samsung reports Q2 EPS KRW 1,613 vs. KRW 1,391 last year
- 10/18/22
- Silvergate Capital reports Q3 EPS $1.28, consensus $1.38
- 07/19/22
- Silvergate Capital reports Q2 EPS $1.13, consensus 84c
- 07/18/22
- Notable companies reporting before tomorrow's open
RTX Raytheon Technologies - 10/25/22
- Raytheon Technologies ups FY22 adjusted EPS view to $4.70-$4.80 from $4.60-$4.80
- 10/25/22
- Raytheon Technologies reports Q3 adjusted EPS $1.21, consensus $1.14
- 10/24/22
- Notable companies reporting before tomorrow's open
- 11/01/22
- Pfizer raises FY22 adjusted EPS view to $6.40-$6.50 from $6.30-$6.45
- 11/01/22
- Pfizer reports Q3 adjusted EPS $1.78, consensus $1.39
- 10/31/22
- Notable companies reporting before tomorrow's open
MDGL Madrigal Pharmaceuticals - 11/03/22
- Madrigal Pharmaceuticals reports Q3 EPS ($4.15), consensus ($4.75)
- 08/04/22
- Madrigal Pharmaceuticals reports Q2 EPS ($4.14) vs ($3.72) last year
- 10/27/22
- Southwest sees FY22 ASMs down 4.5%
- 10/27/22
- Southwest sees Q4 revenue up 13%-17%, consensus $6.23B
- 10/27/22
- Southwest reports Q3 adjusted EPS 50c, consensus 42c
- 10/26/22
- Notable companies reporting before tomorrow's open
- $330.17 /
+4.235 (+1.30%) - 12/08/22
- Lululemon sees FY22 EPS $9.87-$9.97, consensus $9.92
- 12/08/22
- Lululemon sees Q4 EPS $4.20-$4.30, consensus $4.30
- 12/08/22
- Lululemon reports Q3 EPS $2.00, consensus $1.97
- 12/08/22
- Notable companies reporting after market close
- 11/02/22
- Luminar reports Q3 EPS (18c), consensus (20c)
- 11/02/22
- Notable companies reporting after market close
- 08/08/22
- Luminar reports Q2 adjusted EPS (18c), consensus (16c)
- 08/08/22
- Notable companies reporting after market close
- 10/14/22
- JPMorgan reports Q3 EPS $3.12, consensus $2.88
- 10/13/22
- Notable companies reporting before tomorrow's open
- 07/14/22
- JPMorgan reports Q2 EPS $2.76, consensus $2.91
- 10/18/22
- Johnson & Johnson cuts FY22 estimated reported sales view to $93.0B-$93.5B
- 10/18/22
- Johnson & Johnson narrows FY22 adjusted operational EPS view to $10.70-$10.75
- 10/18/22
- Johnson & Johnson narrows FY22 adjusted EPS view to $10.02-$10.07
- 10/18/22
- Johnson & Johnson reports Q3 adjusted EPS $2.55, consensus $2.48
- 01/06/23
- HTG Molecular reports preliminary 2022 revenue $6.4M, two est. $5.7M
- 01/06/23
- Greenbrier reports Q1 adjusted EPS 5c, consensus 50c
- 10/27/22
- Greenbrier sees FY23 revenue $3.2B-$3.6B, consensus $3.03B
- 10/27/22
- Greenbrier reports Q4 EPS 60c, consensus 42c
- 07/11/22
- Greenbrier reports Q3 EPS 9c, consensus 59c
- 11/03/22
- Fate Therapeutics reports Q3 EPS (86c), consensus (89c)
- 08/03/22
- Fate Therapeutics reports Q2 EPS (79c), consensus (83c)
- 01/06/23
- Boot Barn reports preliminary Q3 EPS $1.74, consensus $1.78
- 10/26/22
- Boot Barn cuts FY23 EPS view to $5.70-$5.90 from $6-$6.20, consensus $5.90
- 10/26/22
- Boot Barn sees Q3 EPS $1.71-$1.83, consensus $2.09
- 10/26/22
- Boot Barn Holdings reports Q2 EPS $1.06, consensus 90c
- 10/27/22
- Baxter sees FY22 EPS $3.53- $3.60, consensus $3.62
- 10/27/22
- Baxter sees FY22 revenue growth of 17%-18%, consensus $15.02B
- 10/27/22
- Baxter sees FY22 EPS $3.53- $3.60, consensus $3.62
- 10/27/22
- Baxter reports Q2 EPS 82c, consensus 81c
- 10/17/22
- Bank of America reports Q3 EPS 81c, consensus 77c
- 07/18/22
- Bank of America reports Q2 EPS 73c, consensus 78c
AUPH Aurinia Pharmaceuticals - 01/06/23
- Aurinia Pharmaceuticals backs FY23 net product revenue view $120M-$140M
- 01/06/23
- Aurinia Pharmaceuticals reports preliminary net FY22 revenue $134M
- 01/06/23
- Aurinia Pharmaceuticals reports preliminary Q4 revenue $28.4M, consensus $26.97M
- 11/03/22
- Aurinia Pharmaceuticals lowers FY22 revenue view to $100M-105M from $115M-$135M
- $1.19 /
+0.1974 (+19.89%) - 11/02/22
- Aligos Therapeutics reports Q3 EPS (44c), consensus (58c)
- $88.13 /
+16.08 (+22.32%) - 01/05/23
- Vince McMahon plans to return to WWE to pursue sale, WSJ reports
- 12/13/22
- Vince McMahon faces new demands over assault allegations, WSJ reports
- 11/02/22
- WWE ends probe into alleged misconduct by Vince McMahon, CNBC reports
- 08/17/22
- WWE board finds former CEO McMahon gave $5M to Trump charity, WSJ says
WBD Warner Bros. Discovery - 01/05/23
- Warner Bros. Discovery CFO says 2023 about 'relaunching,' Variety says
- 12/31/22
- Take-Two, Micron had a terrible 2022, could be time to buy, Barron's says
- 12/23/22
- Warner Bros. Discovery backs triathlon start-up, FT reports
- 12/16/22
- Twitter suspends journalists covering Musk, company, NBC News reports
- 01/06/23
- Tesla cuts Model 3, Model Y prices in China after delivery slump, WSJ reports
- 01/04/23
- Tesla files trademark for electric motors 'not for land vehicles,' Electrek says
- 01/03/23
- Tom Zhu becomes Tesla's highest profile executive after Musk, Reuters reports
- 01/03/23
- Tesla fined $2.2M in Korea for violations of advertising law, Bloomberg reports
- 01/05/23
- Samsung's profit could plunge nearly 50% in Q4, CNBC reports
- 01/05/23
- Samsung consumer-gadgets chief tells WSJ he expects tech slump to persist
- 12/28/22
- Samsung expected to start memory price cuts in 2023, DigiTimes reports
- 12/15/22
- Samsung Galaxy S23 to adopt customized AP from Qualcomm, DigiTimes reports
- 01/05/23
- Silvergate Capital has laid off 40% of its staff, WSJ reports
- 12/06/22
- US Senators request information on Silvergate dealings with FTX, NBC reports
- 11/19/22
- Crypto's survival may now depend on Washington, Barron's says
- 11/09/22
- SEC expands probe into FTX, WSJ reports
RTX Raytheon Technologies - 01/06/23
- McCarthy's speaker deal includes $75B defense cut, Bloomberg reports
- 01/05/23
- Raytheon weighs sale of actuation unit, Bloomberg reports
- 01/05/23
- Raytheon weighs sale of actuation unit, Bloomberg reports
- 01/04/23
- Lagging arms production raises concerns over industry consolidation, WSJ report
- 01/06/23
- Pfizer in talks to license Chinese drugmakers for generic Paxlovid, Reuters says
- 12/24/22
- Pfizer, Moderna among vaccine makers to watch in 2023, Barron's says
- 12/14/22
- Warren, Welch tell Pfizer to 'back off' price hike for vaccine, STATNews says
- 12/06/22
- Pfizer dismisses Moderna claim it copied COVID-19 shot, CNBC reports
- 01/06/23
- Southwest meltdown could cost hundreds of millions of dollars, NY Times reports
- 01/05/23
- Southwest to update earnings guidance before Q4 report, Bloomberg says
- 01/05/23
- Southwest to update earnings guidance before Q4 report, Bloomberg says
- 01/04/23
- Southwest offers 25,000 points to travel meltdown-impacted fliers, WSJ reports
- $330.17 /
+4.235 (+1.30%) - 09/30/22
- Peloton tells Bloomberg resolved dispute with Lululemon over athletic wear
- 09/29/22
- Peloton suit against Lululemon thrown out by court, Bloomberg reports
- 09/29/22
- Lululemon wins dismissal of patent suit by Peloton, Bloomberg reports
- 08/17/22
- Lululemon D.C. workers withdraw bid for union vote, Bloomberg reports
- 01/06/23
- Luminar falls after Citron sees shares heading below $1
- 01/06/23
- Luminar shares heading to under $1, Citron Research says
- 10/01/22
- SPAC bubble has burst, Blue Owl Luminar still have potential, Barron's says
- 12/18/22
- JPMorgan said to seal deal to acquire 48.5% of Viva Wallet, Bloomberg reports
- 12/02/22
- Wall Street banks consider bonus cuts up to 30%, Bloomberg reports
- 11/28/22
- JPMorgan, others discuss how to reimburse scammed Zelle customers, WSJ reports
- 11/25/22
- JPMorgan, Deutsche sued by Jeffrey Epstein accusers, WSJ reports
- 12/04/22
- J&J says won't make offer for Horizon Therapeutics, Bloomberg reports
- 11/07/22
- Biogen weighing new CEO options after talks with J&J exec hit impasse, STAT says
- 10/20/22
- CDC panel says COVID shots to be added to regular vaccinations, WSJ says
- 10/20/22
- Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports
- 01/05/23
- Bunzl seen as 'inflation winner', Barrons reports
- 12/03/22
- Tapestry, Saia among small-cap stocks set for big gains, Barron's says
- 09/14/22
- Baxter looks to sell renal-care services, hemodialysis units, Bloomberg reports
- 12/17/22
- Amazon, Google among Barron's 10 favorite stocks for 2023
- 12/09/22
- BofA CEO Moynihan on short list to replace Yellen, Gaparino says via Twitter
AUPH Aurinia Pharmaceuticals - 01/04/23
- Aurinia worth 'keeping closer eye on' after settlement, Dealreporter says
- $88.13 /
+16.08 (+22.32%) - 01/05/23
- Fly Intel: After-Hours Movers
- 08/18/22
- What You Missed On Wall Street This Morning
- 08/16/22
- What You Missed On Wall Street On Tuesday
- 08/16/22
- What You Missed On Wall Street This Morning
WBD Warner Bros. Discovery - 01/02/23
- Box Office Battle: ‘Avatar 2’ wins New Year’s weekend with $86.3M
- 12/26/22
- Box Office Battle: ‘Avatar 2’ wins storm-challenged Christmas weekend
- 12/23/22
- What You Missed On Wall Street This Morning
- 12/18/22
- Box Office Battle: ‘Avatar 2’ wins weekend with $134M debut
- 12/12/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/02/22
- What You Missed On Wall Street On Friday
- 12/02/22
- What You Missed On Wall Street This Morning
- 08/26/22
- What You Missed On Wall Street On Friday
- 01/03/23
- What You Missed On Wall Street On Tuesday
- 01/03/23
- What You Missed On Wall Street This Morning
- 01/03/23
- What You Missed This Week in EVs and Clean Energy
- 01/05/23
- What You Missed On Wall Street On Thursday
- 01/05/23
- What You Missed On Wall Street This Morning
- 12/14/22
- What You Missed On Wall Street On Wednesday
- 12/14/22
- What You Missed On Wall Street This Morning
- 01/06/23
- Here's What You Missed in Crypto This Week
RTX Raytheon Technologies - 12/13/22
- What You Missed On Wall Street On Tuesday
- 12/08/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/15/22
- What You Missed On Wall Street On Tuesday
- 10/25/22
- Fly Intel: Pre-market Movers
- 01/04/23
- What You Missed On Wall Street On Wednesday
- 01/04/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/29/22
- What You Missed On Wall Street This Morning
MDGL Madrigal Pharmaceuticals - 12/21/22
- Biotech Alert: Searches spiking for these stocks today
- 12/19/22
- What You Missed On Wall Street On Monday
- 12/19/22
- What You Missed On Wall Street This Morning
- 12/19/22
- Trial success is rocketing this NASH stock higher and sinking these peers
- 01/06/23
- Fly Intel: Pre-market Movers
- 01/04/23
- What You Missed On Wall Street This Morning
- 12/29/22
- What You Missed On Wall Street On Thursday
- 12/28/22
- Fly Intel: Pre-market Movers
- $330.17 /
+4.235 (+1.30%) - 12/09/22
- What You Missed On Wall Street On Friday
- 12/09/22
- What You Missed On Wall Street This Morning
- 12/09/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/09/22
- Fly Intel: Pre-market Movers
- 01/04/23
- Fly Intel: After-Hours Movers
- 10/31/22
- What You Missed This Week in EVs and Clean Energy
- 09/26/22
- What You Missed This Week in EVs and Clean Energy
- 09/22/22
- What You Missed On Wall Street On Thursday
- 12/08/22
- Fly Intel: Pre-market Movers
- 12/06/22
- What You Missed On Wall Street On Tuesday
- 12/05/22
- What You Missed On Wall Street On Monday
- 11/30/22
- What You Missed On Wall Street On Wednesday
- 07/11/22
- What You Missed On Wall Street On Monday
- 07/11/22
- What You Missed On Wall Street This Morning
- 01/06/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/22/22
- What You Missed On Wall Street On Thursday
- 10/26/22
- Fly Intel: After-Hours Movers
- 08/11/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 10/27/22
- Fly Intel: Pre-market Movers
- 10/18/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 09/14/22
- What You Missed On Wall Street This Morning
- 07/28/22
- Fly Intel: Pre-market Movers
- 11/14/22
- What You Missed On Wall Street On Monday
AUPH Aurinia Pharmaceuticals - 01/05/23
- Biotech Alert: Searches spiking for these stocks today
WBD Warner Bros. Discovery - 01/03/23
- Early notable gainers among liquid option names on January 3rd
- 12/29/22
- Early notable gainers among liquid option names on December 29th
- 12/21/22
- Warner Bros. Discovery call volume above normal and directionally bullish
- 12/06/22
- Warner Bros. Discovery put volume heavy and directionally bearish
- 12/01/22
- Ulta Beauty options imply 5.0% move in share price post-earnings
- 10/11/22
- Early notable gainers among liquid option names on October 11th
- 08/26/22
- Early notable gainers among liquid option names on August 26th
- 08/25/22
- Ulta Beauty options imply 5.6% move in share price post-earnings
- 01/06/23
- Notable open interest changes for January 6th
- 01/05/23
- Notable open interest changes for January 5th
- 01/04/23
- Notable open interest changes for January 4th
- 01/03/23
- Notable open interest changes for January 3rd
- 01/06/23
- Largest borrow rate increases among liquid names
- 01/05/23
- Largest borrow rate increases among liquid names
- 12/21/22
- Largest borrow rate increases among liquid names
- 12/13/22
- Silvergate Capital Corp put volume heavy and directionally bearish
RTX Raytheon Technologies - 10/25/22
- Unusually active option classes on open October 25th
- 10/24/22
- Unusually active option classes on open October 24th
- 10/10/22
- Raytheon Technologies call volume above normal and directionally bullish
- 08/22/22
- Raytheon Technologies call volume above normal and directionally bullish
- 11/14/22
- Pfizer call volume above normal and directionally bullish
- 11/01/22
- Unusually active option classes on open November 1st
- 10/21/22
- Unusually active option classes on open October 21st
- 08/19/22
- Early notable gainers among liquid option names on August 19th
MDGL Madrigal Pharmaceuticals - 12/23/22
- Largest borrow rate increases among liquid names
- 12/21/22
- Madrigal Pharmaceuticals put volume heavy and directionally bearish
- 12/05/22
- Madrigal Pharmaceuticals put volume heavy and directionally bearish
- 12/30/22
- Unusually active option classes on open December 30th
- 12/29/22
- Unusually active option classes on open December 29th
- 12/28/22
- Unusually active option classes on open December 28th
- 12/27/22
- Unusually active option classes on open December 27th
- $330.17 /
+4.235 (+1.30%) - 01/04/23
- Lululemon put volume heavy and directionally bearish
- 12/21/22
- Unusually active option classes on open December 21st
- 12/12/22
- Unusually active option classes on open December 12th
- 12/08/22
- Lululemon options imply 6.9% move in share price post-earnings
- 12/06/22
- Luminar Technologies put volume heavy and directionally bearish
- 11/02/22
- Luminar Technologies options imply 9.1% move in share price post-earnings
- 10/14/22
- Notable open interest changes for October 14th
- 09/28/22
- Notable open interest changes for September 28th
- 12/05/22
- JPMorgan put volume heavy and directionally bearish
- 11/30/22
- JPMorgan put volume heavy and directionally bearish
- 10/14/22
- Early notable gainers among liquid option names on October 14th
- 10/14/22
- Unusually active option classes on open October 14th
- 12/22/22
- Johnson & Johnson put volume heavy and directionally bearish
- 11/11/22
- Johnson & Johnson put volume heavy and directionally bearish
- 10/18/22
- Unusually active option classes on open October 18th
- 09/20/22
- Johnson & Johnson put volume heavy and directionally bearish
- 01/05/23
- Baxter call volume above normal and directionally bullish
- 12/14/22
- Baxter put volume heavy and directionally bearish
- 08/31/22
- Early notable gainers among liquid option names on August 31st
- 01/03/23
- Bank of America call volume above normal and directionally bullish
- 12/07/22
- Notable open interest changes for December 7th
- 12/06/22
- Notable open interest changes for December 6th
- 11/07/22
- Bank of America call volume above normal and directionally bullish
AUPH Aurinia Pharmaceuticals - 01/06/23
- Aurinia Pharmaceuticals call volume above normal and directionally bullish
- 07/27/22
- Aurinia Pharmaceuticals call volume above normal and directionally bullish
|
Downgrade
|
Wells Fargo analyst Ike… Wells Fargo analyst Ike Boruchow downgraded Ulta Beauty to Underweight from Equal Weight with a price target of $400, down from $450. The space is coming off its worst year since the global financial crisis as demand broke down, inventory ballooned, and costs spiked, and Boruchow sees a very challenging catalyst path heading into 2023, the analyst tells investors in a research note. Additionally, holiday results were likely "OK" at best, and with a difficult Q1 setup looming, Street numbers that will likely be coming down on weaker initial guidance, the analyst contends. ShowHide Related Items >><< - 12/05/22
- Ulta Beauty CEO: Consumer is loving what we are offering
- 12/01/22
- Ulta Beauty reports SSS up 14.6% y/y
- 10/07/22
- Tanger Factory announces first Ulta Beauty store opening in Rehoboth Beach
- 09/07/22
- Jeld-Wen appoints Halligan to board of directors
- 01/06/23 Wells Fargo
- Ulta Beauty downgraded to Underweight from Equal Weight at Wells Fargo
- 01/05/23 Argus
- Ulta Beauty price target raised to $530 from $455 at Argus
- 12/12/22 Goldman Sachs
- Ulta Beauty downgraded to Neutral from Buy at Goldman Sachs
- 12/05/22 Barclays
- Ulta Beauty price target raised to $548 from $511 at Barclays
- 12/01/22
- Ulta Beauty raises FY22 EPS view to $22.60-$22.90 from $20.70-$21.20
- 12/01/22
- Ulta Beauty raises FY22 revenue view to $9.95B-$10.0B from $9.65B-$9.75B
- 12/01/22
- Ulta Beauty reports Q3 EPS $5.34, consensus $4.15
- 12/01/22
- Notable companies reporting after market close
- 12/12/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/02/22
- What You Missed On Wall Street On Friday
- 12/02/22
- What You Missed On Wall Street This Morning
- 08/26/22
- What You Missed On Wall Street On Friday
- 12/01/22
- Ulta Beauty options imply 5.0% move in share price post-earnings
- 10/11/22
- Early notable gainers among liquid option names on October 11th
- 08/26/22
- Early notable gainers among liquid option names on August 26th
- 08/25/22
- Ulta Beauty options imply 5.6% move in share price post-earnings
|
Downgrade
|
Wells Fargo analyst Ike… Wells Fargo analyst Ike Boruchow downgraded Ulta Beauty to Underweight from Equal Weight with a price target of $400, down from $450. ShowHide Related Items >><< - 12/05/22
- Ulta Beauty CEO: Consumer is loving what we are offering
- 12/01/22
- Ulta Beauty reports SSS up 14.6% y/y
- 10/07/22
- Tanger Factory announces first Ulta Beauty store opening in Rehoboth Beach
- 09/07/22
- Jeld-Wen appoints Halligan to board of directors
- 01/05/23 Argus
- Ulta Beauty price target raised to $530 from $455 at Argus
- 12/12/22 Goldman Sachs
- Ulta Beauty downgraded to Neutral from Buy at Goldman Sachs
- 12/05/22 Barclays
- Ulta Beauty price target raised to $548 from $511 at Barclays
- 12/02/22 DA Davidson
- Ulta Beauty price target raised to $545 from $490 at DA Davidson
- 12/01/22
- Ulta Beauty raises FY22 EPS view to $22.60-$22.90 from $20.70-$21.20
- 12/01/22
- Ulta Beauty raises FY22 revenue view to $9.95B-$10.0B from $9.65B-$9.75B
- 12/01/22
- Ulta Beauty reports Q3 EPS $5.34, consensus $4.15
- 12/01/22
- Notable companies reporting after market close
- 12/12/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/02/22
- What You Missed On Wall Street On Friday
- 12/02/22
- What You Missed On Wall Street This Morning
- 08/26/22
- What You Missed On Wall Street On Friday
- 12/01/22
- Ulta Beauty options imply 5.0% move in share price post-earnings
- 10/11/22
- Early notable gainers among liquid option names on October 11th
- 08/26/22
- Early notable gainers among liquid option names on August 26th
- 08/25/22
- Ulta Beauty options imply 5.6% move in share price post-earnings
|
Recommendations
|
Argus analyst Kristina… Argus analyst Kristina Ruggeri raised the firm's price target on Ulta Beauty to $530 from $455 and keeps a Buy rating on the shares. The analyst is positive on the company's business partnerships, loyalty programs, strong customer engagement, and new focus on wellness. Ruggeri also cites Ulta's most recent operating margin of 15.5% coming in at a record high. The analyst is raising her FY23 EPS view on the stock to $22.75 from $21.00 and her FY24 view to $23.82 from $22.55. ShowHide Related Items >><< - 12/05/22
- Ulta Beauty CEO: Consumer is loving what we are offering
- 12/01/22
- Ulta Beauty reports SSS up 14.6% y/y
- 10/07/22
- Tanger Factory announces first Ulta Beauty store opening in Rehoboth Beach
- 09/07/22
- Jeld-Wen appoints Halligan to board of directors
- 12/12/22 Goldman Sachs
- Ulta Beauty downgraded to Neutral from Buy at Goldman Sachs
- 12/05/22 Barclays
- Ulta Beauty price target raised to $548 from $511 at Barclays
- 12/02/22 DA Davidson
- Ulta Beauty price target raised to $545 from $490 at DA Davidson
- 12/02/22 Deutsche Bank
- Ulta Beauty price target raised to $607 from $589 at Deutsche Bank
- 12/01/22
- Ulta Beauty raises FY22 EPS view to $22.60-$22.90 from $20.70-$21.20
- 12/01/22
- Ulta Beauty raises FY22 revenue view to $9.95B-$10.0B from $9.65B-$9.75B
- 12/01/22
- Ulta Beauty reports Q3 EPS $5.34, consensus $4.15
- 12/01/22
- Notable companies reporting after market close
- 12/12/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/02/22
- What You Missed On Wall Street On Friday
- 12/02/22
- What You Missed On Wall Street This Morning
- 08/26/22
- What You Missed On Wall Street On Friday
- 12/01/22
- Ulta Beauty options imply 5.0% move in share price post-earnings
- 10/11/22
- Early notable gainers among liquid option names on October 11th
- 08/26/22
- Early notable gainers among liquid option names on August 26th
- 08/25/22
- Ulta Beauty options imply 5.6% move in share price post-earnings
|
Over a month ago |
On The Fly
| ShowHide Related Items >><< - 12/05/22
- Ulta Beauty CEO: Consumer is loving what we are offering
- 12/01/22
- Ulta Beauty reports SSS up 14.6% y/y
- 10/07/22
- Tanger Factory announces first Ulta Beauty store opening in Rehoboth Beach
- 09/07/22
- Jeld-Wen appoints Halligan to board of directors
- 11/18/22
- Adtalem Global Education appoints Blake Simpson as CCO
- 10/05/22
- Under Armour announces executive leadership changes
- 08/03/22
- Under Armour sees 'overabundance' of product hitting the market in 2022
- 08/03/22
- Under Armour's Plank says Browne in running for permanent CEO job
- 12/04/22
- Fly Intel: Top five weekend stock stories
- 09/09/22
- Tapestry announces long-term financial targets
- 08/04/22
- Tapestry COO Tom Glaser retires, Scott Roe to succeed
- 11/15/22
- Royal Gold raises annual dividend to $1.50 from $1.40 per share
- 11/02/22
- Royal Gold sees FY22 sales at midpoint of 315K-340K GEOs
- 08/03/22
- Royal Gold backs guidance for sales of 315,000 to 340,000 GEOs
- 08/02/22
- Royal Gold acquires royalty interest on Cortez mine in Nevada for $525M
- 11/02/22
- Qualcomm falls 7% to $104.90 after Q1 guidance misses estimates
- 11/02/22
- Qualcomm sees low-double digits handset volume declines for 2022
- 10/25/22
- Cognizant expands collaboration with Qualcomm
- 09/30/22
- L&T Technology Services, Qualcomm collaborate to deploy end-to-end 5G solutions
- 11/02/22
- Palomar sees FY22 adjusted net income $82M-$85M
- 10/20/22
- Palomar announces Q3 estimated pretax catastrophe losses of $12.5M
- 07/26/22
- Palomar announces new partnership with Omaha National Group
- 12/06/22
- Micron ships Micron 2550 NVMe SSD to global PC OEM customers
- 11/29/22
- Micron CFO says pricing has trended 'well below' expectations
- 11/16/22
- Micron down 5% after warning outlook for 2023 has weakened
- 11/16/22
- Micron announces further actions to address market conditions
- $450.50 /
+0.275 (+0.06%) - 12/11/22
- Fly Intel: Top five weekend stock stories
- 11/16/22
- Wafer Fab Equipment names slide after Micron cuts wafer starts
- 11/15/22
- Lam Research acquires SEMSYSCO GmbH, terms not disclosed
- 10/20/22
- Velo3D appoints Jessie Lockhart as chief people officer
- 11/14/22
- Jana made new buy Freshpet top holding in Q3, also bought Momentive
- 10/13/22
- Labcorp appoints Google Cloud exec Kliphouse to board of directors
- 08/23/22
- Labcorp closes acquisition of RWJBarnabas Health outreach laboratory business
- 08/15/22
- JANA Partners exits Zendesk, boosts stake in New Relic
- 12/05/22
- European Commission says Illumina has to unwind Grail acquisition
- 11/02/22
- Twist Bioscience and Illumina team on robust exome panel for research
- 10/18/22
- Illumina enters partnership with GenoScreen in effort to end tuberculosis
- 10/11/22
- Illumina launches strategic research collaboration with AstraZeneca
- 11/17/22
- Gap rises 8% to nearly $14 after Q3 results
- 11/10/22
- Gap launches collection of 'family essentials' with Amazon Fashion
- 10/25/22
- Gap 'taking immediate steps' to remove Yeezy Gap product from stores
- 09/28/22
- Gap unit Athleta teams with thredUP, and Shop Premium Outlets for online
- 11/29/22
- Nevada reports October statewide gaming win up 4.83% to $1.28B
- 11/29/22
- Churchill Downs, DraftKings enter agreement to develop, launch DK HORSE
- 11/21/22
- DraftKings sees no evidence that company systems were breached
- 11/21/22
- DraftKings says less than $300,000 of customer funds impacted by compromises
- 12/02/22
- Coinbase says Apple blocked last app release on NFTs
- 11/30/22
- Coinbase Wallet to stop supporting BCH, ETC, XLM, XRP
- 11/21/22
- Crypto names down in pre-market as bitcoin falls to one-week low
- 11/16/22
- Cathie Wood's ARK Investment bought 245.6K shares of Coinbase today
- 11/10/22
- Becton Dickinson increases quarterly dividend 4.6% to 91c per share
- 10/18/22
- Becton Dickinson, Magnolia announce co-exclusive commercial agreement
- 10/18/22
- Becton Dickinson, Biocorp enter self-administered drug therapies tracking pact
- 10/06/22
- AngioDynamics 'disappointed' in verdict in antitrust action against C.R. Bard
- 11/22/22
- Best Buy rises 9.5%
- 11/22/22
- Best Buy jumps 8% to $76.17 after Q3 earnings beat and comps outlook update
- 11/22/22
- Best Buy sees FY23 comparable sales down approximately 10%
- 11/22/22
- Genesco appoints Best Buy CFO Matthew Bilunas to board
- 08/15/22
- Allied Motion names Ken May as CTO
- 08/04/22
- Allied Motion trading resumes
- 08/04/22
- Allied Motion trading halted, volatility trading pause
- 12/12/22 Goldman Sachs
- Tapestry upgraded to Buy from Neutral at Goldman Sachs
- 11/29/22 JPMorgan
- Tapestry price target raised to $47 from $46 at JPMorgan
- 11/14/22 Citi
- Tapestry price target lowered to $40 from $42 at Citi
- 11/11/22 Morgan Stanley
- Tapestry price target lowered to $35 from $39 at Morgan Stanley
- 12/12/22 Goldman Sachs
- Gap upgraded to Buy from Neutral at Goldman Sachs
- 11/21/22 Deutsche Bank
- Gap price target raised to $11 from $8 at Deutsche Bank
- 11/21/22 Barclays
- Gap price target raised to $14 from $9 at Barclays
- 11/18/22 Jefferies
- Gap price target raised to $13 from $11 at Jefferies
- 12/12/22 Goldman Sachs
- Best Buy upgraded to Neutral from Sell at Goldman Sachs
- 11/28/22 Goldman Sachs
- Goldman finds small crowds, more promotions over Black Friday weekend
- 11/28/22 Wedbush
- Black Friday winners Include Best Buy, losers include Pets, says Wedbush
- 11/23/22 BofA
- Best Buy price target raised to $80 from $75 at BofA
- 12/12/22 Stifel
- Under Armour upgraded to Buy from Hold at Stifel
- 11/07/22 JPMorgan
- Under Armour price target raised to $11 from $10 at JPMorgan
- 11/01/22 BofA
- Under Armour reinstated with a Neutral at BofA
- 10/31/22 JPMorgan
- Under Armour price target lowered to $10 from $12 at JPMorgan
- 12/12/22 Citi
- Becton Dickinson upgraded to Neutral from Sell at Citi
- 12/12/22 Citi
- Becton Dickinson upgraded to Neutral from Sell at Citi
- 11/16/22 Evercore ISI
- Evercore ISI removes seven Healthcare Services and Tech stocks from 'TAP' list
- 11/14/22 Citi
- Becton Dickinson price target lowered to $220 from $227 at Citi
- $450.50 /
+0.275 (+0.06%) - 12/12/22 Deutsche Bank
- Lam Research upgraded to Buy from Hold at Deutsche Bank
- 10/20/22 Jefferies
- Lam Research price target lowered to $525 from $535 at Jefferies
- 10/20/22 Evercore ISI
- Lam Research price target lowered to $450 from $500 at Evercore ISI
- 10/20/22 Wells Fargo
- Lam Research price target lowered to $350 from $410 at Wells Fargo
- 12/12/22 Wells Fargo
- Wells Fargo downgrades Qualcomm to Underweight with $105 price target
- 12/12/22 Wells Fargo
- Qualcomm downgraded to Underweight from Equal Weight at Wells Fargo
- 11/15/22 Credit Suisse
- Qualcomm initiated with an Outperform at Credit Suisse
- 11/03/22 KeyBanc
- Qualcomm price target lowered to $150 from $170 at KeyBanc
- 12/12/22 Deutsche Bank
- Micron downgraded to Hold from Buy at Deutsche Bank
- 12/07/22 Wells Fargo
- Micron price target lowered to $70 from $75 at Wells Fargo
- 12/05/22 Lynx
- Micron price target raised to $60 from $56 at Lynx
- 11/30/22 Stifel
- Micron management's tone 'incrementally downbeat,' says Stifel
- 12/12/22 Roth MKM
- Roth Capital downgrades DraftKings to Neutral, keeps $15 price target
- 12/12/22 Roth MKM
- DraftKings downgraded to Neutral from Buy at Roth Capital
- 11/29/22 JMP Securities
- DraftKings deal with Churchill an attractive opportunity, says JMP Securities
- 11/29/22 Piper Sandler
- Piper sees 'several' positives in DraftKings horse racing pact
- 12/12/22 Goldman Sachs
- Ulta Beauty downgraded to Neutral from Buy at Goldman Sachs
- 12/05/22 Barclays
- Ulta Beauty price target raised to $548 from $511 at Barclays
- 12/02/22 DA Davidson
- Ulta Beauty price target raised to $545 from $490 at DA Davidson
- 12/02/22 Deutsche Bank
- Ulta Beauty price target raised to $607 from $589 at Deutsche Bank
- 12/12/22 Citi
- Illumina downgraded to Sell from Neutral at Citi
- 12/12/22 Citi
- Illumina downgraded to Sell from Neutral at Citi
- 12/06/22 RBC Capital
- Illumina initiated with an Outperform at RBC Capital
- 12/06/22 Canaccord
- Illumina divestment for GRAIL buy worth the wait, says Canaccord
- 12/12/22 Citi
- Labcorp downgraded to Neutral from Buy at Citi
- 12/12/22 Citi
- Labcorp downgraded to Neutral from Buy at Citi
- 11/30/22 Wells Fargo
- Bust of smuggling ring likely to beheadwind for LabCorp, says Wells Fargo
- 11/17/22 Citi
- Quest Diagnostics downgraded to Sell from Neutral at Citi
- 12/12/22 KeyBanc
- Coinbase initiated with a Sector Weight at KeyBanc
- 12/12/22 Mizuho
- Fiserv price target lowered to $135 from $145 at Mizuho
- 12/09/22 Mizuho
- Coinbase downgraded to Underperform from Neutral at Mizuho
- 12/05/22 Atlantic Equities
- Coinbase price target lowered to $46 from $67 at Atlantic Equities
- 12/12/22 Northland
- Allied Motion initiated with an Outperform at Northland
- 12/12/22 Jefferies
- Palomar initiated with a Hold at Jefferies
- 11/07/22 Barclays
- Palomar price target lowered to $93 from $102 at Barclays
- 10/18/22 JMP Securities
- Palomar downgraded to Market Perform from Outperform at JMP Securities
- 10/14/22 Barclays
- Palomar price target raised to $102 from $80 at Barclays
KNSL Kinsale Capital Group - 12/12/22 Jefferies
- Kinsale Capital Group initiated with a Hold at Jefferies
- 10/31/22 Truist
- Kinsale Capital Group price target raised to $335 from $285 at Truist
- 10/31/22 RBC Capital
- Kinsale Capital Group price target raised to $350 from $275 at RBC Capital
- 08/15/22 Compass Point
- Kinsale Capital Group downgraded to Neutral from Buy at Compass Point
- 12/12/22 Credit Suisse
- Royal Gold initiated with a Neutral at Credit Suisse
- 10/17/22 Barclays
- Royal Gold price target lowered to $108 from $110 at Barclays
- 08/05/22 Raymond James
- Royal Gold price target lowered to C$142 from C$144 at Raymond James
- 07/21/22 National Bank
- Royal Gold price target lowered to $150 from $165 at National Bank
- 12/01/22
- Ulta Beauty raises FY22 EPS view to $22.60-$22.90 from $20.70-$21.20
- 12/01/22
- Ulta Beauty raises FY22 revenue view to $9.95B-$10.0B from $9.65B-$9.75B
- 12/01/22
- Ulta Beauty reports Q3 EPS $5.34, consensus $4.15
- 12/01/22
- Notable companies reporting after market close
- 11/03/22
- Under Armour cuts FY23 EPS view to 56c-60c from 61c-67c, consensus 43c
- 11/03/22
- Under Armour reports Q2 adjusted EPS 20c, consensus 16c
- 11/02/22
- Notable companies reporting before tomorrow's open
- 11/10/22
- Tapestry sees FY23 EPS $3.60-$3.70, consensus $3.82
- 11/10/22
- Tapestry reports Q1 EPS 79c, consensus 75c
- 11/09/22
- Notable companies reporting before tomorrow's open
- 11/02/22
- Royal Gold reports Q3 adjusted EPS 71c, consensus 73c
- 08/03/22
- Royal Gold reports Q2 adjusted EPS 81c, consensus 91c
- 11/02/22
- Qualcomm sees Q1 adjusted EPS adjusted EPS $2.25-$2.45, consensus $3.42
- 11/02/22
- Qualcomm reports Q4 adjusted EPS $3.13, consensus $3.13
- 11/02/22
- Notable companies reporting after market close
- 07/27/22
- Qualcomm sees Q4 adjusted EPS $3.00-$3.30, consensus $3.23
- 11/02/22
- Palomar reports Q3 EPS 29c, consensus 51c
- 08/03/22
- Palomar reports Q2 EPS 73c, consensus 67c
- 09/29/22
- Micron sees Q2 revenue range similar to Q1
- 09/29/22
- Micron sees Q1 adjusted EPS 4c, plus or minus 10c, consensus 64
- 09/29/22
- Micron reports Q4 adjusted EPS $1.45, consensus $1.30
- 09/29/22
- Notable companies reporting after market close
- $450.50 /
+0.275 (+0.06%) - 10/19/22
- Lam Research sees Q2 EPS $10.00 +/- 75c, consensus $9.47
- 10/19/22
- Lam Research reports Q1 EPS $10.42, consensus $9.53
- 10/19/22
- Notable companies reporting after market close
- 07/27/22
- Lam Research sees Q1 EPS $8.75-$10.25, consensus $8.82
- 10/27/22
- Labcorp sees FY22 EPS $19.25- $20.25 , consensus $20.19
- 10/27/22
- Labcorp reports Q3 EPS $4.68, consensus $4.67
- 07/28/22
- LabCorp raises FY22 adjusted EPS view to $19.00-$21.25 from $18.25-$21.00
- 07/28/22
- LabCorp reports Q2 adjusted EPS $4.96, consensus $4.70
KNSL Kinsale Capital Group - 10/27/22
- Kinsale Capital Group reports Q3 EPS $1.64, consensus $1.30
- 07/28/22
- Kinsale Capital reports Q2 operating EPS $1.92, consensus $1.62
- 11/03/22
- Illumina sees FY22 adjusted EPS $2.35-$2.50, consensus $2.78
- 11/03/22
- Illumina reports Q3 adjusted EPS 34c, consensus 30c
- 11/03/22
- Notable companies reporting after market close
- 10/03/22
- Illumina sees giving detailed FY23 guidance in February
- 11/17/22
- Gap reports Q3 Gap brand revenue $1.04B, flat y/y
- 11/17/22
- Gap sees Q4 revenue down mid-single digits, consensus $4.5B
- 11/17/22
- Gap reports Q3 adjusted EPS 71c, consensus 0c
- 11/17/22
- Notable companies reporting after market close
- 11/04/22
- DraftKings sees 2023 revenue $2.8B-$3B, consensus $2.83B
- 11/04/22
- DraftKings raises 2022 revenue view $2.16B-$2.19B from $2.08B-$2.18B
- 11/04/22
- DraftKings reports Q3 revenue $502M, consensus $437.23M
- 11/03/22
- Notable companies reporting before tomorrow's open
- 12/07/22
- Coinbase CEO tells Bloomberg 2022 revenue seen down 50% or more
- 11/03/22
- Coinbase reports Q3 EPS ($2.43), consensus ($2.40)
- 08/09/22
- Coinbase reports Q2 EPS ($4.98), consensus ($2.65)
- 11/10/22
- Becton Dickinson sees FY23 adjusted EPS $11.85-$12.10, consensus $12.19
- 11/10/22
- Becton Dickinson reports Q4 adjusted EPS $2.75, consensus $2.74
- 11/22/22
- Best Buy reports Q3 EPS $1.38, consensus $1.03
- 11/21/22
- Notable companies reporting before tomorrow's open
- 08/30/22
- Best Buy reports Q2 EPS$1.54, consensus $1.27
|
Downgrade
|
Goldman Sachs analyst… Goldman Sachs analyst Kate McShane downgraded Ulta Beauty to Neutral from Buy with a price target of $508, down from $511. The company's market share gains from here are likely to be "more limited" and it faces difficult year-over-year compares following a strong 2022, McShane tells investors in a research note. In addition, Ulta's margin risk "skews to the downside" given a high level of investing next year and its current valuation suggests limited upside, says the analyst. ShowHide Related Items >><< - 12/05/22
- Ulta Beauty CEO: Consumer is loving what we are offering
- 12/01/22
- Ulta Beauty reports SSS up 14.6% y/y
- 10/07/22
- Tanger Factory announces first Ulta Beauty store opening in Rehoboth Beach
- 09/07/22
- Jeld-Wen appoints Halligan to board of directors
- 12/05/22 Barclays
- Ulta Beauty price target raised to $548 from $511 at Barclays
- 12/02/22 DA Davidson
- Ulta Beauty price target raised to $545 from $490 at DA Davidson
- 12/02/22 Deutsche Bank
- Ulta Beauty price target raised to $607 from $589 at Deutsche Bank
- 12/02/22 Baird
- Ulta Beauty price target raised to $550 from $500 at Baird
- 12/01/22
- Ulta Beauty raises FY22 EPS view to $22.60-$22.90 from $20.70-$21.20
- 12/01/22
- Ulta Beauty raises FY22 revenue view to $9.95B-$10.0B from $9.65B-$9.75B
- 12/01/22
- Ulta Beauty reports Q3 EPS $5.34, consensus $4.15
- 12/01/22
- Notable companies reporting after market close
- 12/02/22
- What You Missed On Wall Street On Friday
- 12/02/22
- What You Missed On Wall Street This Morning
- 08/26/22
- What You Missed On Wall Street On Friday
- 08/26/22
- What You Missed On Wall Street This Morning
- 12/01/22
- Ulta Beauty options imply 5.0% move in share price post-earnings
- 10/11/22
- Early notable gainers among liquid option names on October 11th
- 08/26/22
- Early notable gainers among liquid option names on August 26th
- 08/25/22
- Ulta Beauty options imply 5.6% move in share price post-earnings
|
Hot Stocks
|
In an interview on… In an interview on CNBC's Mad Money, Dave Kimbell said Ulta saw broad based strength across the business in Q3. The company's positive culture is holding it together and attracting new talent, Kimball said. "We are staffed and ready to go for the holiday season." Ulta continues to bring in new customers and reactivate old ones, with Gen Z representing a strong growth opportunity, Kimbell noted. ShowHide Related Items >><< - $472.42 /
+0.865 (+0.18%) - 12/01/22
- Ulta Beauty reports SSS up 14.6% y/y
- 10/07/22
- Tanger Factory announces first Ulta Beauty store opening in Rehoboth Beach
- 09/07/22
- Jeld-Wen appoints Halligan to board of directors
- 08/25/22
- Ulta Beauty reports Q2 comparable sales up 14.4%
- $472.42 /
+0.865 (+0.18%) - 12/05/22 Barclays
- Ulta Beauty price target raised to $548 from $511 at Barclays
- 12/02/22 DA Davidson
- Ulta Beauty price target raised to $545 from $490 at DA Davidson
- 12/02/22 Deutsche Bank
- Ulta Beauty price target raised to $607 from $589 at Deutsche Bank
- 12/02/22 Baird
- Ulta Beauty price target raised to $550 from $500 at Baird
- $472.42 /
+0.865 (+0.18%) - 12/01/22
- Ulta Beauty raises FY22 EPS view to $22.60-$22.90 from $20.70-$21.20
- 12/01/22
- Ulta Beauty raises FY22 revenue view to $9.95B-$10.0B from $9.65B-$9.75B
- 12/01/22
- Ulta Beauty reports Q3 EPS $5.34, consensus $4.15
- 12/01/22
- Notable companies reporting after market close
- $472.42 /
+0.865 (+0.18%) - 12/02/22
- What You Missed On Wall Street On Friday
- 12/02/22
- What You Missed On Wall Street This Morning
- 08/26/22
- What You Missed On Wall Street On Friday
- 08/26/22
- What You Missed On Wall Street This Morning
- $472.42 /
+0.865 (+0.18%) - 12/01/22
- Ulta Beauty options imply 5.0% move in share price post-earnings
- 10/11/22
- Early notable gainers among liquid option names on October 11th
- 08/26/22
- Early notable gainers among liquid option names on August 26th
- 08/25/22
- Ulta Beauty options imply 5.6% move in share price post-earnings
|